

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 295/32, 295/205, 211/58, 211/46, 211/34, 211/26, 243/08, 493/04, C07C 279/18, 271/24, 271/20, A61K 31/325, 31/155, 31/445, 31/495		A1	(11) International Publication Number: WO 96/09297 (43) International Publication Date: 28 March 1996 (28.03.96)
(21) International Application Number: PCT/US95/11814 (22) International Filing Date: 14 September 1995 (14.09.95) (30) Priority Data: 08/312,269 23 September 1994 (23.09.94) US		(81) Designated States: AU, BY, CA, CN, CZ, EE, FI, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RU, SG, SI, SK, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant: ARRIS PHARMACEUTICAL CORPORATION [US/US]; 385 Oyster Point Boulevard, South San Francisco, CA 94080 (US). (72) Inventors: RICE, Ken, D.; 1380 Oak Creek Drive #409, Palo Alto, CA 94304 (US). DENER, Jeffrey, M.; 850 Campus Drive #106, Daly City, CA 94015 (US). GANGLOFF, Anthony, R.; 2723 South Norfolk Street #306, San Mateo, CA 94403 (US). KUO, Elaine, Yee-Lin; One St. Francis Place #6102, San Francisco, CA 94107 (US). (74) Agents: DOW, Karen, B. et al.; Townsend and Townsend and Crew, Steuart Street Tower, 20th floor, One Market Plaza, San Francisco, CA 94105 (US).			
(54) Title: COMPOSITIONS AND METHODS FOR TREATING MAST-CELL INFLAMMATORY CONDITION			
(57) Abstract Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

5

COMPOSITIONS AND METHODS FOR TREATING MAST-CELL INFLAMMATORY CONDITIONS

BACKGROUND OF THE INVENTION

10 This application is a continuation-in-part of U.S. Application Serial No. 08/312,269, filed September 23, 1994, which is incorporated herein by reference in its entirety for all purposes.

15 1. Field of the Invention

This invention relates to compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders. The invention includes compositions and methods effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis. The compositions and methods of the present invention are especially useful for preventing or treating the late phase bronchoconstriction and airway hyperresponsiveness associated with chronic asthma. In addition, the compositions and methods of the present invention have utility in treating other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, as well as various dermatological conditions. Further, the compositions and methods of the present invention have utility in the treatment of respiratory syncytial virus.

2. Description of the Background Art

Asthma is a complex disease involving multiple biochemical mediators for both its acute and chronic manifestations. Increasingly, asthma is recognized as an inflammatory disorder (see, e.g., Hood, et al., IMMUNOLOGY 2nd ed., Benjamin-Cummings 1984). Asthma frequently is characterized by progressive development of hyperresponsiveness of the trachea and bronchi to both immunospecific allergens and

generalized chemical or physical stimuli. The hyperresponsiveness of asthmatic bronchiolar tissue is believed to result from chronic inflammation reactions, which irritate and damage the epithelium lining the airway wall and promote pathological thickening of the underlying tissue. Bronchial biopsy studies have indicated that even patients with mild asthma have features of inflammation in the airway wall.

One initiator of the inflammatory sequence is an allergic response to inhaled allergens. Leukocytes carrying IgE receptors, notably mast cells and basophils, but also including monocytes, macrophages, and eosinophils, are present in the epithelium and underlying smooth muscle tissues of bronchi where they are activated initially by binding of specific inhaled antigens to the IgE receptors. Activated mast cells release a number of preformed or primary chemical mediators of the inflammatory response and enzymes. Furthermore, numerous secondary mediators of inflammation are generated *in situ* by enzymatic reactions of activated mast cells, including superoxide and lipid derived mediators. In addition, several large molecules are released by degranulation of mast cells: proteoglycans, peroxidase, arylsulfatase B, and notably the proteases tryptase and chymotryptic proteinase (chymase). See DRUG THERAPY OF ASTHMA, pp. 1054-54.

This chemical release from mast cells probably accounts for the early bronchiolar constrictor response that occurs in susceptible individuals after exposure to airborne allergens. The early asthmatic reaction is maximal at around fifteen minutes after allergen exposure; recovery occurs over the ensuing one to two hours. In 25-35% of individuals, the early asthmatic reaction is followed by a further decline in respiratory function which begins within a few hours and is maximal between six and twelve hours post-exposure. This late asthmatic reaction is accompanied by a marked increase in the number of inflammatory cells infiltrating bronchiolar smooth muscle and epithelial tissues, and spilling into the airways. These cells include eosinophils, neutrophils, and lymphocytes, all of which are attracted to the site by release of mast cell derived chemotactic agents. The infiltrating cells themselves

become activated during the late reaction phase. The late asthmatic response is believed to be a secondary inflammatory reaction mediated in part by the secretory activity of macrophages.

5 Tryptase is the major secretory protease of human mast cells and is proposed to be involved in neuropeptide processing and tissue inflammation. Mature human tryptase is a glycosylated, heparin-associated tetramer of heterogenous, catalytically active subunits. See, e.g., Vanderslice et al. 10 Proc. Natl. Acad. Sci. USA 87:3811-3815 (1990); Miller et al. J. Clin. Invest. 86:864-870 (1990); Miller et al. J. Clin. Invest. 84:1188-1195 (1989); and Vanderslice et al. Biochemistry 28:4148-4155 (1989).

15 Tryptase is stored in mast cell secretory granules. After mast cell activation, human tryptase can be measured readily in a variety of biologic fluids. For example, after anaphylaxis, tryptase appears in the bloodstream, where it remains detectable for several hours. See Schwartz et al., N. Engl. J. Med. 316:1622-1626 (1987). Its appearance has been 20 detected in samples of nasal and lung lavage fluid from atopic subjects challenged with specific antigen. See Castells and Schwartz, J. Allerg. Clin. Immunol. 82:348-355 (1988) and Wenzel, et al., Am. Rev. Resp. Dis. 141:563-568 (1988). Tryptase levels in lung lavage fluid obtained from atopic 25 asthmatics increase after endobronchial allergen challenge. Some smokers of cigarettes have striking elevations of bronchoalveolar lavage fluid tryptase levels compared to nonsmoker control groups, a finding that provides some support for the hypothesis that release of proteinases from activated 30 mast cells could contribute to lung destruction in smoker's emphysema. See Kalenderian, et al., Chest 94:119-123 (1988). In addition, tryptase has been shown to be a potent mitogen for fibroblasts, suggesting its involvement in pulmonary fibrosis and interstitial lung diseases. See Ruoss et al., J. Clin. 35 Invest. 88:493-499 (1991).

Tryptase has been implicated in a variety of biological processes, including degradation of vasodilating and bronchorelaxing neuropeptides (see Caughey, et al., J.

Pharmacol. Exp. Ther. 244:133-137 (1988); Franconi, et al., *J. Pharmacol. Exp. Ther.* 248:947-951 (1988); and Tam, et al., *Am. J. Respir. Cell Mol. Biol.* 3:27-32 (1990)) and modulation of bronchial responsiveness to histamine (see Sekizawa, et al., *J. Clin. Invest.* 83:175-179 (1989)). These studies suggest that tryptase possibly increases bronchoconstriction in asthma by destroying bronchodilating peptides.

Additionally, tryptase has been shown to cleave fibrinogen α -chains, as well as high molecular weight kininogen with a possible release of kinins and thus, may play a role with heparin as a local anticoagulant. The ability of tryptase to activate prostromelysin (pro-MMP-3) and procollagenase (pro-MMP-1) via MMP-3 suggests that tryptase also may be involved in tissue inflammation and remodeling. This finding also intimates that tryptase may play a role in joint destruction in rheumatoid arthritis. In addition, tryptase has been shown to cleave calcitonin gene-related peptide. As this peptide is implicated in neurogenic inflammation, tryptase could be a factor in the regulation of flare reaction in cutaneous neurogenic inflammation. See Caughey, *Am. J. Respir. Cell Mol. Biol.* 4:387-394 (1991).


Respiratory syncytial virus has also been found to be the cause of human respiratory disorders. This virus has been implicated as a leading cause of respiratory tract infection in infancy and childhood, such as bronchiolitis and bronchopneumonia. Certain compounds, specifically, aromatic amidino derivatives, generally recognized as inhibitors of trypsin, urokinase and plasmin, have been shown to be effective in blocking cell fusion induced by respiratory syncytial virus, and significantly reducing the yield of the virus. See R.R. Tidwell, et al., *J. Med. Chem.* 26(2):294-298 (1983), and Tidwell, et al., *Antimicrobial Agents and Chemotherapy* 26:591 (1984).

Mast cell mediated inflammatory conditions and syncytial viral infections are a growing public health concern. In particular, asthma has become a common chronic disease in industrialized countries. Therefore, it would be desirable to

provide improved compositions and methods for providing effective treatment for these diseases.

SUMMARY OF THE INVENTION

5 The present invention provides symmetrical compounds of the formula:



in which:

Z is amino, guanidino or amidino;

10 Y is optionally substituted cyclo(C₃₋₁₄)alkylene or optionally substituted heterocyclo(C₃₋₁₄)alkylene;

X¹ is optionally substituted (C₃₋₆)alkylene, optionally substituted oxa(C₄₋₆)alkylene or -X⁶-X⁷-X⁸- (wherein X⁷ is optionally substituted phenylene, optionally substituted

15 cyclo(C₃₋₆)alkylene, or optionally substituted heterocyclo(C₃₋₆)alkylene and X⁶ and X⁸ are optionally substituted (C_{n6})alkylene and optionally substituted (C_{n8})alkylene, respectively, wherein the sum of n₆ and n₈ is equal to 1, 2, 3 or 4, with the proviso that when Z is amino n₆ is not 0); X²


20 and X⁴ are independently -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(R¹)-, -N(R¹)C(O)-, -OC(O)N(R¹)-, -N(R¹)C(O)O-, -N(R¹)C(O)N(R¹)- or -OC(O)O- (wherein each R¹ is independently

hydrogen, optionally substituted (C₁₋₈)alkyl or optionally substituted cyclo(C₃₋₈)alkyl); X³ is optionally substituted (C₁₋₈)alkylene, -X⁹-X¹⁰- or -X¹⁰-X⁹- (wherein X⁹ is optionally

25 substituted (C_{n9})alkylene, wherein n₉ is 0, 1 or 2, and X¹⁰ is optionally substituted cyclo(C₃₋₈)alkylene or optionally substituted heterocyclo(C₃₋₈)alkylene, with the proviso that covalent bonds do not occur between hetero atoms contained

30 within X¹⁰ and hetero atoms contained within either X² or X⁴); and X⁵ is optionally substituted (C_{n5})alkylene wherein n₅ is 0, 1 or 2; and the pharmaceutically acceptable salts and prodrugs thereof.

The present invention provides unsymmetrical
35 compounds of the formula:



in which R² and R³ are independently Z-X¹-X²-X³-X⁴-X⁵-

in which:

Z is amino, guanidino or amidino;

Y is optionally substituted cyclo(C₃₋₁₄)alkylene or optionally substituted heterocyclo(C₃₋₁₄)alkylene;

5 X¹ is optionally substituted (C₃₋₆)alkylene, optionally substituted oxa(C₄₋₆)alkylene or -X⁶-X⁷-X⁸- (wherein X⁷ is optionally substituted phenylene, optionally substituted cyclo(C₃₋₆)alkylene or optionally substituted heterocyclo(C₃₋₆)alkylene and X⁶ and X⁸ are optionally substituted

10 (C_{n6})alkylene and optionally substituted (C_{n8})alkylene, respectively, wherein the sum of n₆ and n₈ is equal to 1, 2, 3 or 4, with the proviso that when Z is amino n₆ is not 0);

X² and X⁴ are independently -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(R¹)-, -N(R¹)C(O)-, -OC(O)N(R¹)-, -N(R¹)C(O)O-,

15 -N(R¹)C(O)N(R¹)-, -OC(O)O- (wherein each R¹ is independently hydrogen, optionally substituted (C₁₋₈)alkyl or optionally substituted cyclo(C₃₋₈)alkyl; X³ is optionally substituted (C₁₋₈)alkylene, -X⁹-X¹⁰- or -X¹⁰-X⁹- (wherein X⁹ is optionally substituted (C_{n9})alkylene, wherein n₉ is 0, 1 or 2, and X¹⁰ is

20 optionally substituted cyclo(C₃₋₈)alkylene or optionally substituted heterocyclo(C₃₋₈)alkylene, with the proviso that covalent bonds do not occur between hetero atoms contained within X¹⁰ and hetero atoms contained within either X² or X⁴);

X⁵ is optionally substituted (C_{n5})alkylene wherein n₅ is 0, 1

25 or 2; with the proviso that R² and R³ are not the same; and the pharmaceutically acceptable salts and prodrugs thereof.

The present invention provides pharmaceutical compositions comprising a compound of this invention or a pharmaceutically acceptable salt or salts thereof in admixture with one or more suitable excipients and said compositions further comprising a β -adrenergic agonist.

The present invention provides methods for treating an immunomediated inflammatory disorder of the respiratory tract of a mammal, said method comprising administering to said mammal a therapeutically effective amount of a compound of this invention or a pharmaceutically acceptable salt or salts thereof or a pharmaceutical composition containing said

compound, salt or salts or said composition further comprising a β -adrenergic agonist.

The present invention provides a method for treating immunomediated inflammatory skin conditions, rheumatoid

5 arthritis, conjunctivitis or syncytial virus infection in a mammal, said method comprising administering to said mammal a therapeutically effective amount of a compound of this invention or a pharmaceutically acceptable salt or salts thereof or a pharmaceutical composition containing said

10 compound, salt or salts.

The pharmaceutical compositions of the present invention can be in a variety of forms including oral dosage forms, inhalable forms, as well as injectable and infusible solutions. When used in inhalant or aerosol form, the

15 compounds of the present invention are used in combination with a pharmaceutically acceptable carrier solution or dry powder which can be converted into aerosol form. Similarly, when used in oral administration, the compounds of the present invention are used in combination with a pharmaceutically acceptable carrier suitable for such oral administration. When used for the treatment of immunomediated inflammatory skin conditions, the compounds of the present invention are used in combination with a non-toxic, pharmaceutically acceptable topical carrier.

20 The compounds of the present invention can be used in combination with antiinflammatories or other asthma therapies, such as β -adrenergic agonists, antiinflammatory corticosteroids, anticholinergics, bronchodilators such as methyl xanthenes and the like.

25 The compounds described herein are useful for the prevention and treatment of immunomediated inflammatory disorders, and particularly those associated with the respiratory tract, including asthma, and particularly the hyperresponsiveness phase associated with chronic asthma, and allergic rhinitis. Thus, the present invention also provides a

30 method for treating immunomediated inflammatory disorders wherein a patient having an immunomediated inflammatory disorder is administered a therapeutically effective dose or amount of a compound of the present invention. Further, the

compounds described herein are useful for treating syncytial viral infections.

BRIEF DESCRIPTION OF THE DRAWINGS

5 Figure 1 is a graphical representation of the Specific Lung Resistance (SRL) as a function of time (in hours) of antigen-challenged sheep treated with *cis*-1,5-cyclooctylene bis[4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate] (Compound 3) by aerosol administration of 3, 50 μ g doses, versus
10 sheep treated with a control.

Figure 2 is a bar chart showing the airway hyperresponsiveness (measured as PC400) of antigen-challenged sheep treated with *cis*-1,5-cyclooctylene bis[4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate] (Compound 15 3) by aerosol administration of 3, 50 μ g doses, versus sheep treated with a control.

Figure 3 is a graphical representation of the Specific Lung Resistance (SRL) as a function of time (in hours) of antigen-challenged sheep treated with *cis*-1,5-cyclooctylene bis[4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate] (Compound 20 3) by oral administration of 3, 2 mg doses, versus sheep treated with a control.

Figure 4 is a bar chart showing the airway hyperresponsiveness (measured as PC400) antigen-challenged 25 sheep treated with *cis*-1,5-cyclooctylene bis[4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate] (Compound 3) by oral administration of 3, 2 mg doses, versus sheep treated with a control.

Figure 5 is a graphical representation of the Specific Lung Resistance (SRL) as a function of time (in hours) 30 of antigen-challenged sheep treated with *cis*-1,5-cyclooctylene bis(4-guanidinobenzylcarbamoylmethylaminocarboxylate) (Compound 2) by aerosol administration of 3, 0.1 mg doses, versus sheep treated with a control.

35 Figure 6 is a bar chart showing the airway hyperresponsiveness (measured as PC400) antigen-challenged sheep treated with *cis*-1,5-cyclooctylene bis(4-guanidinobenzylcarbamoylmethylaminocarboxylate) (Compound

2) by aerosol administration of 3, 0.1 mg doses, versus sheep treated with a control.

Figure 7 is a graphical representation of the Specific Lung Resistance (SRL) as a function of time (in hours) of antigen-challenged sheep pretreated with *cis*-1,5-cyclooctylene bis[4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate] (Compound 3) by aerosol administration of 0.5 mg per day for three days, with an additional 0.5 mg dose one half hour before antigen challenge, versus sheep treated with a control.

Figure 8 is a bar chart showing the airway hyperresponsiveness (measured as PC400) antigen-challenged sheep pretreated with *cis*-1,5-cyclooctylene bis[4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate] (Compound 3) by aerosol administration of 0.5 mg per day for three days, with an additional 0.5 mg dose one half hour before antigen challenge, versus sheep treated with a control.

DESCRIPTION OF THE PREFERRED EMBODIMENT

I. Definitions

The following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.

"Immunomediated inflammatory disorder" includes generally those diseases associated with mast cell mediator release and susceptible to treatment with a tryptase inhibitor. Examples of such disorders include diseases of immediate type hypersensitivity such as asthma, allergic rhinitis, urticaria and angioedema, and eczematous dermatitis (atopic dermatitis), and anaphylaxis, as well as hyperproliferative skin disease, peptic ulcers, inflammatory bowel disorder, ocular and vernal conjunctivitis, rheumatoid arthritis, inflammatory skin conditions, and the like.

"Hyperresponsiveness" refers to late phase bronchoconstriction and airway hyperreactivity associated with chronic asthma. Hyperresponsiveness of asthmatic bronchiolar tissue is believed to result from chronic inflammation reactions, which irritate and damage the epithelium lining the

airway wall and promote pathological thickening of the underlying tissue.

"Halogen" refers to fluorine, bromine, chlorine, and iodine atoms.

5 "Hydroxyl" refers to the group -OH.

"Amino" refers to the group -NH₂.

"Oxa" as used herein refers to the divalent oxygen group -O-.

"Thiol" or "mercapto" refers to the group -SH.

10 The term "(C₁₋₈)alkoxy" denotes the group -OR, where R is (C₁₋₈)alkyl, substituted (C₁₋₈)alkyl, aryl, substituted aryl, aralkyl or substituted aralkyl as defined below.

15 "Alkyl", as in (C₁₋₄)alkyl or (C₁₋₈)alkyl, refers to straight or branched saturated hydrocarbon radical having from one to the number of carbon atoms designated. This term is further exemplified by such groups as methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, i-butyl, i-pentyl, n-pentyl, hexyl and the like. "Optionally substituted (C₁₋₈)alkyl" refers to an alkyl radical as defined above optionally substituted with 20 one or more functional groups such as halogen, hydroxyl, amino, -NRR' (wherein R and R' are independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted acyl), mercapto or an optionally substituted group selected from (C₁₋₈)alkyl, (C₃₋₈)cycloalkyl, aryl, aryl(C₁₋₄)alkyl, acyl, (C₁₋₈)alkyloxy, aryloxy, cyclo(C₃₋₈)alkyloxy, aryl(C₁₋₄)alkyloxy, 25 (C₁₋₈)alkylthio, arylthio, cyclo(C₃₋₈)alkylthio, aryl(C₁₋₄)alkylthio, acyloxy and the like.

30 "Cycloalkyl", as in cyclo(C₃₋₈)alkyl, refers to a saturated monocyclic hydrocarbon having the number of carbon atoms designated. This term is further exemplified by such groups as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like. "Optionally substituted cyclo(C₃₋₈)alkyl" refers to a cycloalkyl radical as defined above optionally substituted with one or more functional groups such as halogen, hydroxyl, amino, -NRR' (wherein R and R' are independently hydrogen, 35 optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted aryl or optionally

substituted acyl), mercapto or an optionally substituted group selected from (C_{1-8})alkyl, cyclo(C_{3-8})alkyl, aryl, aryl(C_{1-4})alkyl, acyl, (C_{1-8})alkyloxy, aryloxy, cyclo(C_{3-8})alkyloxy, aryl(C_{1-4})alkyloxy, (C_{1-8})alkylthio, arylthio, cyclo(C_{3-8})alkylthio, aryl(C_{1-4})alkylthio, acyloxy and the like.

"Aryl" refers to an organic radical derived from an aromatic hydrocarbon containing 6 to 14 carbon atoms and includes monocyclic or condensed carbocyclic aromatic rings such as phenyl, naphthyl, anthracenyl, phenanthrenyl and the like. "Optionally substituted aryl" refers to an aryl radical as defined above optionally substituted with one or more functional groups such as halogen, hydroxyl, amino, -NRR' (wherein R and R' are independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, 10 optionally substituted aryl or optionally substituted acyl), mercapto or an optionally substituted group selected from (C_{1-8})alkyl, cyclo(C_{3-8})alkyl, aryl, aryl(C_{1-4})alkyl, acyl, (C_{1-8})alkyloxy, aryloxy, cyclo(C_{3-8})alkyloxy, aryl(C_{1-4})alkyloxy, (C_{1-8})alkylthio, arylthio, cyclo(C_{3-8})alkylthio, aryl(C_{1-4})alkylthio, acyloxy and the like.

"Alkyloxy", as in (C_{1-3})alkyloxyl or (C_{1-8})alkyloxy, denotes the group -OR, wherein R is optionally substituted alkyl as defined above.

"Aryloxy", "cycloalkyloxy" and "aryl(C_{1-4})alkyloxy" denote the group -OR, wherein R is optionally substituted aryl, optionally substituted cycloalkyl and optionally substituted aryl(C_{1-4})alkyl, respectively, as defined above.

"Alkylthio" denotes the group -SR, wherein which R is optionally substituted alkyl as defined above.

"Arylthio", "cycloalkylthio" and "aryl(C_{1-4})alkylthio" denote the group -SR, wherein R is optionally substituted aryl, optionally substituted cycloalkyl or optionally substituted aryl(C_{1-4})alkyl, respectively, as defined above.

"Acyl" denotes the group -C(O)R, wherein R is optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted aryl as defined above.

"Acyloxy" denotes the group $-OC(O)R$, wherein R is optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted aryl as defined above.

5 "Amino(C_{1-4})alkyl", "amino(C_{1-4})alkyloxy" and "amino(C_{1-4})alkenyl" refer to an alkyl, alkyloxy or alkenyl radical as defined above, wherein an amino group is attached to the terminal ($\Omega-$) carbon of the radical.

10 "Alkylene", for the purposes of this application, refers to a saturated or unsaturated, divalent radical having the number of carbon atoms designated. This term is further exemplified by such groups as methylene ($-CH_2-$), ethylene ($-CH_2CH_2-$), trimethylene ($-CH_2CH_2CH_2-$) and the like.

15 "Optionally substituted alkylene" refers to a divalent radical as defined above optionally substituted with one or more functional groups such as halogen, hydroxyl, amino, $-NRR'$ (wherein R and R' are independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted acyl), mercapto or an optionally substituted group selected from (C_{1-8})alkyl, (C_{3-8})cycloalkyl, aryl, aryl(C_{1-4})alkyl, acyl, (C_{1-8})alkyloxy, aryloxy, cyclo(C_{3-8})alkyloxy, aryl(C_{1-4})alkyloxy, (C_{1-8})alkylthio, arylthio, cyclo(C_{3-8})alkylthio, aryl(C_{1-4})alkylthio, acyloxy and the like.

20 "Oxaalkylene," as in oxa(C_{4-6})alkylene, denotes the divalent radical $-R-O-R'-$, wherein R and R' are independently alkylene as defined above, having the number of atoms designated. This term is further exemplified by such groups as 2-oxatrimethylene ($-CH_2-O-CH_2-$), 2-oxatetramethylene ($-CH_2-O-CH_2CH_2-$), 3-oxatetramethylene ($-CH_2CH_2-O-CH_2-$), 3-oxapentamethylene ($-CH_2CH_2-O-CH_2CH_2-$), 3-oxahexamethylene ($-CH_2CH_2-O-CH_2CH_2CH_2-$), and the like. "Optionally substituted oxaalkylene" refers to a divalent radical as defined above, optionally substituted with one or more functional groups such as halogen, hydroxyl, amino, $-NRR'$ (wherein R and R' are independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted acyl), mercapto or an optionally substituted group selected from (C_{1-8})alkyl, cyclo(C_{1-4})alkyl,

aryl, aryl(C₁₋₄)alkyl, acyl, (C₁₋₈)alkyloxy, aryloxy, cyclo(C₃₋₈)alkyloxy, aryl(C₁₋₄)alkyloxy, (C₁₋₈)alkylthio, arylthio, cyclo(C₃₋₈)alkylthio, aryl(C₁₋₄)alkylthio, acyloxy and the like.

"Cycloalkylene," as in cyclo(C₃₋₁₄)alkylene, for the

5 purposes of this application, refers to a cyclic or polycyclic, saturated or nonaromatic unsaturated divalent radical having from 3 to the number of carbon atoms indicated. This term is further exemplified by such groups as cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, cyclohexenylene,
10 bicyclohexylene, bicyclohexenylene, cyclooctylene and the like.
"Optionally substituted cycloalkylene" refers to a divalent radical as defined above optionally substituted with one or more functional groups such as halogen, hydroxyl, amino, -NRR' (wherein R and R' are independently hydrogen, optionally
15 substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted acyl), mercapto or an optionally substituted group selected from (C₁₋₈)alkyl, (C₃₋₈)cycloalkyl, aryl, aryl(C₁₋₄)alkyl, acyl, (C₁₋₈)alkyloxy, aryloxy, cyclo(C₃₋₈)alkyloxy, aryl(C₁₋₄)alkyloxy,
20 (C₁₋₈)alkylthio, arylthio, cyclo(C₃₋₈)alkylthio, aryl(C₁₋₄)alkylthio, acyloxy and the like.

"Heterocycloalkylene", for the purposes of this

application, refers to a cyclic or polycyclic, saturated or nonaromatic unsaturated divalent radical having from 3 to the
25 number of atoms indicated, one or more of which are hetero atoms chosen from N, O or S. This term is further exemplified by such groups as 1,5-dioxaoctylene,
4,8-dioxabicyclo[3.3.0]octylene and the like. "Optionally substituted heterocycloalkylene" refers to a divalent radical as defined above optionally substituted with one or more
30 functional groups such as halogen, hydroxyl, amino, -NRR' (wherein R and R' are independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted acyl),
35 mercapto or an optionally substituted group selected from (C₁₋₈)alkyl, (C₃₋₈)cycloalkyl, aryl, aryl(C₁₋₄)alkyl, acyl, (C₁₋₈)alkyloxy, aryloxy, cyclo(C₃₋₈)alkyloxy, aryl(C₁₋₄)alkyloxy,

(C₁₋₈)alkylthio, arylthio, cyclo(C₃₋₈)alkylthio, aryl(C₁₋₄)alkylthio, acyloxy and the like.

"Pharmaceutically acceptable salt" refers to those salts which retain the biological effectiveness and properties 5 of the parent compound and which are not biologically or otherwise undesirable.

"Prodrug" refers to a compound which, upon administration, undergoes chemical conversion by *in vivo* metabolic processes.

10 "Optionally" refers to an event or circumstance which may or may not occur, and the description includes instances when the event or circumstance occurs and when it does not. For example, the phrase "optionally substituted (C₁₋₈)alkyl" refers to an alkyl group which may or may not contain further 15 substitutions. Both circumstances would fall within the scope of the present invention.

20 "Pharmaceutically or therapeutically acceptable carrier" refers to a carrier medium which does not interfere with the effectiveness of the biological activity of the active ingredients and which is not toxic to the host or patient.

25 "Stereoisomer" refers to a chemical compound having the same molecular weight, chemical composition, and constitution as another, but with the atoms grouped differently. That is, certain identical chemical moieties are at different orientations in space and, therefore, when pure, have the ability to rotate the plane of polarized light. However, some pure stereoisomers may have an optical rotation that is so slight that it is undetectable with present instrumentation. The compounds of the present invention may 30 have one or more asymmetrical carbon atoms and therefore include various stereoisomers. All stereoisomers are included within the scope of the invention.


35 "Treatment" or "treating" refers to any administration of a compound of the present invention *in vitro* or *in vivo* and includes:

- (i) inhibiting the symptoms of the disease; and/or
- (ii) lessening or inhibiting the long term effects of the disease.

The compounds of this invention are named in accordance with acceptable nomenclature rules generally consistent with "Chemical Abstracts". For example, the compound in which n5 is 0, z-X¹- is 4-guanidinobenzyl, X² is -NHC(O)-, X³ is 1,4-piperazinylene, X⁴ is -C(O)O- and Y is cis-1,5-cyclooctylene, is named cis-1,5-cyclooctylene bis[4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate]; the compound in which n5 is 1, z-X¹- is trans-4-aminomethylcyclohexylmethyl, X² is -NHC(O)-, X³ is 1,4-piperazinylene, X⁴ is -C(O)O- and Y is trans-1,4-cyclohexylene is named trans-1,4-cyclohexylenedimethylene bis[4-(trans-4-aminomethylcyclohexylmethylcarbamoyl)-1-piperazinecarboxylate]; the compound in which n5 is 0, z-X¹- is 4-(2-aminoethyl)phenyl, X² is -C(O)-, X³ is 1,4-piperazinylene, X⁴ is -C(O)O- and Y is cis-1,5-cyclooctylene is named cis-1,5-cyclooctylene bis{4-[4-(2-aminoethyl)benzoyl]-1-piperazinecarboxylate}; and the compound in which n5 is 0, z-X¹- is trans-4-aminomethylcyclohexyl, X² is -NHC(O)O-, X³ is ethylene, X⁴ is -N(CH₃)C(O)O- and Y is cis-1,5-cyclooctylene is named cis-1,5-cyclooctylene bis {N-2-(trans-4-aminomethylcyclohexylaminoformyloxy)ethyl-N-methylaminocarboxylate}.

25 II. Compounds

The present invention provides symmetrical compounds of the formula:



in which:

30 Z is amino, guanidino or amidino;
 Y is optionally substituted cyclo(C₃₋₁₄)alkylene or optionally substituted heterocyclo(C₃₋₁₄)alkylene;
 X¹ is optionally substituted (C₃₋₆)alkylene, optionally substituted oxa(C₄₋₆)alkylene or -X⁶-X⁷-X⁸- (wherein X⁷ is
 35 optionally substituted phenylene, optionally substituted cyclo(C₃₋₆)alkylene or optionally substituted heterocyclo(C₃₋₆)alkylene and X⁶ and X⁸ are optionally substituted (C_{n6})alkylene and optionally substituted (C_{n8})alkylene,

respectively, wherein the sum of n₆ and n₈ is equal to 1, 2, 3 or 4, with the proviso that when Z is amino n₆ is not 0); X² and X⁴ are independently -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(R¹)-, -N(R¹)C(O)-, -OC(O)N(R¹)-, -N(R¹)C(O)O-, -N(R¹)C(O)N(R¹)- or -OC(O)O- (wherein each R¹ is independently hydrogen, optionally substituted (C₁₋₈)alkyl or optionally substituted cyclo(C₃₋₈)alkyl); X³ is optionally substituted (C₁₋₈)alkylene, -X⁹-X¹⁰- or -X¹⁰-X⁹- (wherein X⁹ is optionally substituted (C_{n9})alkylene, wherein n₉ is 0, 1, 2, and X¹⁰ is optionally substituted 5 cyclo(C₃₋₈)alkylene or optionally substituted heterocyclo(C₃₋₈)alkylene, with the proviso that covalent bonds do not occur between hetero atoms contained within X¹⁰ and hetero atoms 10 contained within either X² or X⁴); and X⁵ is optionally substituted (C_{n5})alkylene wherein n₅ is 0, 1, 15 2; and the pharmaceutically acceptable salts thereof.

While the broadest definition of this invention is set forth in the Summary of the invention certain compounds of the invention are preferred. For example, generally preferred are those compounds in which Z is amino, n₆ is 1 or 2, n₈ is 1 20 and X⁶ is 1,4-phenylene, 1,4-cyclohexylene, 1,4-bicyclo[2.2.2]octylene, 1,4-bicyclo[2.2.1]heptylene, 1,3-phenylene, 1,3-cyclohexylene, 1,3-bicyclo[2.2.2]octylene, 1,3-bicyclo[2.2.1]heptylene, or Z is guanidino or amidino, n₆ 25 is 0, n₈ is 1 and X⁶ is 1,4-phenylene or 1,3-phenylene; X² is -C(O)-, -C(O)NH-, or -NHC(O)O-; X³ is 1,4-piperazinylene, 1,4-piperidylene, 1,4-perhydro-7H-1,4-diazepinylene or -X⁹-X¹⁰- (wherein X⁹ is methylene and X¹⁰ is 1,4-piperidylene) and X⁴ is 30 -C(O)- or -C(O)O-; or X³ is (C₁₋₄)alkyne and X⁴ is -N(R¹)C(O)O- (wherein R¹ is hydrogen or methyl); and Y is cyclooctylene, cyclohexylene, cyclopentylene, cis-decahydronaphthylene, trans-decahydronaphthylene, perhydrophenanthrene, bicyclo[2.2.1]heptylene, bicyclo[2.2.2]octylene, bicyclo[3.3.1]nonylene, dioxabicyclo[3.3.0]octylene or tetracyclo[3.3.1.1^{3,7}]decylene.

More preferred are those compounds in which Z is amino, n₆ and n₈ are each 1 and X¹ is trans-1,4-cyclohexylene or Z is guanidino or amidino, n₆ is 0, n₈ is 1 and X¹ is 1,4-phenylene; X² is -C(O)- or -NHC(O)O-; X³ is 35 1,4-piperazinylene;

X^4 is $-C(O)O-$; and $n5$ is 0 and Y is cis-1,5-cyclooctylene or $n5$ is 2 and Y is trans-cyclohexylene.

Examples of especially preferred compounds include:

trans-1,4-cyclohexylenedimethylene bis(4-

5 guanidinobenzylcarbamoylmethylaminocarboxylate), alternatively written in IUPAC nomenclature as 1,1'-*trans*-1,4-bis(4-cyclohexylenedimethylene bis[N-(*p*-guanidylbenzyl)glycinamide]-(N)-(α)-carboxylate];
10 *cis*-1,5-cyclooctylene bis(4-guanidinobenzylcarbamoylmethylaminocarboxylate), alternatively written in IUPAC nomenclature as 1,1'-*cis*-1,5-cyclooctylene bis[N-4-(*p*-guanidylbenzyl)glycinamide]-(N)-α-carboxylate];
cis-1,5-cyclooctylene bis[4-(4-guanidinobenzylcarbomoyl)-1-piperazinecarboxylate];
15 *cis*-1,5-cyclooctylene bis[4-(*trans*-4-aminomethylcyclohexylmethylcarbamoyl)-1-piperazinecarboxylate]; and
cis-1,5-cyclooctylene bis[4-(4-guanidinophenylacetyl)-1-piperazinecarboxylate].

Generally, the compounds of the invention are

20 synthesized using standard techniques and reagents. It will be noted that the linkages between the various groups, x^1 , x^2 , x^3 , x^4 and x^5 comprise carbons linked to the nitrogen of an amide or carbamate, the oxygen of a carbamate or urea or the carbon of a carbonyl. Those of skill in the art will recognize that
25 methods and reagents for forming these bonds are well known and readily available. See, e.g., March, ADVANCED ORGANIC CHEMISTRY, 4th Ed. (Wiley 1992), Larock, COMPREHENSIVE ORGANIC TRANSFORMATIONS (VCH 1989); and Furniss, et al., VOGEL'S TEXTBOOK OF PRACTICAL ORGANIC CHEMISTRY 5th ed. (Longman 1989), each of which is
30 incorporated herein by reference. It will also be appreciated that any functional groups present may require protection and deprotection at different points in the synthesis of the compounds of the invention. Those of skill in the art will also recognize that such techniques are well known (see, e.g.,
35 Green and Wuts, PROTECTIVE GROUPS IN ORGANIC CHEMISTRY (Wiley 1991), also incorporated herein by reference).

The various groups x^1 , x^2 , x^3 , x^4 and x^5 which comprise the compounds of this invention can be assembled

individually or as larger combinations thereof. For example, compounds of the invention wherein X^3 is methylene and X^4 is $-\text{NHC(O)O}-$ can be prepared by first reacting an appropriate cycloalkylenediol (e.g., *cis*-1,5-cyclooctanediol, *trans*-1,4-5 cyclohexylenedimethanol, etc.) with an excess of a suitable isocyanatoacetate to form the formyloxy linkage between X^4 and X^5 , or Y when n_5 is 0, hydrolyzing to give the corresponding dicarboxylic acid and then reacting the dicarboxylic acid with an appropriate protected amine (e.g., 4-tert-10 butoxycarbonylaminobenzylamine, etc.) in the presence of a suitable coupling agent.

Alternatively, an appropriate cycloalkylenediol is converted to a corresponding bis-chloroformate by treating with phosgene which is reacted with an appropriate mono-protected 15 diamine to form a formyloxy linkage between X^3 and X^5 , or Y when n_5 is 0, deprotecting to give the corresponding intermediate with two reactive amines and then reacting the unprotected intermediate with an appropriate protected isocyanate (e.g., 4-tert-butoxycarbonylaminophenylmethyl 20 isocyanate, etc.), deprotecting and performing any necessary last step reaction (e.g., converting an aminophenyl group to a guanidinophenyl). Compounds of the invention in which X^2 is $-\text{C(O)}-$ can be prepared by proceeding as above but reacting the unprotected intermediate with an appropriate carboxylic acid 25 (e.g., 4-aminobenzoic acid, 4-aminomethylbenzoic acid, etc.). Compounds of the invention in which Z is substituted with guanidino can be prepared from a corresponding bis(amine) by reacting with amino cyanamide. Compounds of the invention in which Z is amidino can be prepared from a corresponding 30 bis(nitrile) by treating with hydrogen chloride and ethanol followed by exposure to ammonia. The reaction steps described in this and the preceding paragraph can be performed by methods known to those of ordinary skill in the art.

The present invention provides unsymmetrical 35 compounds of the formula:



in which R^2 and R^3 are independently $\text{Z}-\text{X}^1-\text{X}^2-\text{X}^3-\text{X}^4-\text{X}^5-$

in which:

Z is amino, guanidino or amidino;

Y is optionally substituted cyclo(C₃₋₁₄)alkylene or optionally substituted heterocyclo(C₃₋₁₄)alkylene;

5 X¹ is optionally substituted (C₃₋₆)alkylene, optionally substituted oxa(C₄₋₆)alkylene or -X⁶-X⁷-X⁸- (wherein X⁷ is optionally substituted phenylene, optionally substituted cyclo(C₃₋₆)alkylene or optionally substituted heterocyclo(C₃₋₆)alkylene and X⁶ and X⁸ are optionally substituted

10 (C_{n6})alkylene and optionally substituted (C_{n8})alkylene, respectively, wherein the sum of n₆ and n₈ is equal to 1, 2, 3 or 4, with the proviso that when Z is amino n₆ is not 0); X² and X⁴ are independently -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(R¹)-, -N(R¹)C(O)-, -OC(O)N(R¹)-, -N(R¹)C(O)O- (wherein

15 each R¹ is independently hydrogen, optionally substituted (C₁₋₈)alkyl or optionally substituted cyclo(C₄₋₈)alkyl); X³ is optionally substituted (C₁₋₈)alkylene, -X⁹-X¹⁰- or -X¹⁰-X⁹- (wherein X⁹ is optionally substituted (C_{n9})alkylene, wherein n₉ is 0, 1 or 2, and X¹⁰ is optionally substituted cyclo(C₃₋₈)alkylene or optionally substituted heterocyclo(C₃₋₈)alkylene,

20 with the proviso that covalent bonds do not occur between hetero atoms contained within X¹⁰ and hetero atoms contained within either X² or X⁴); X⁵ is optionally substituted (C_{n5})alkylene wherein n₅ is 0, 1 or 2; with the proviso that R² and R³ are not the same; and the pharmaceutically acceptable salts thereof.

The unsymmetrical compounds of the invention can be prepared by proceeding analogously to that described herein for preparing symmetrical compounds of the invention but introducing various X¹, X², X³, X⁴, and X⁵ groups independently. For example, compounds of the invention in which -X⁴-X⁵- or R² and R³ are the same and the Z-X¹-X²-X³- of R² and R³ are different can be prepared by converting an appropriate cycloalkylenediol to a corresponding bis-chloroformate, reacting the bis-chloroformate with one molar equivalent of an appropriate mono-protected diamine to give the corresponding monochloroformate, reacting the monochloroformate with an appropriate mono-protected diamine to give a compound of the

formula $P-X^4-X^5-Y-X^5-X^4-P'$, wherein P and P' are each chemically distinct protecting groups (e.g., tert-butoxycarbonyl and benzyl), orthogonally removing one or the other protecting group and then proceeding as described above for the preparation of the symmetrical compounds of the invention. Appropriate protecting groups and the methods for selectively deprotecting are known to those of ordinary skill in the art. Those of skill in the art would recognize that analogous methods can be employed to prepare other unsymmetrical compounds of the invention in which the Z, X^1 , X^2 , X^3 , X^4 and X^5 of R^2 and R^3 independently vary.

In some cases, X^3 will be selected from the group consisting of heterocycloalkylene and substituted heterocycloalkylene, e.g., piperazine, homopiperazine and hydroxypiperidine. These groups may be added individually in analogy to the above methodologies or formed *in situ* from appropriately functionalized alkynes using commonly known synthetic techniques such as those described in March, Larock of Furniss, *supra*.

Those of skill in the art will also appreciate that the linking group $-X^1-X^2-X^3-X^4-$ and the various subgroups thereof, may be formed by techniques well known in the art and by analogy to the examples provided herein as well. It will also be appreciated that amino acids provide convenient building blocks from which to create the various functionalities which comprise the linking group $-X^1-X^2-X^3-X^4-$. The amino acids used herein include the twenty naturally occurring L-amino acids and their D- enantiomers as well as their derivatives. Amino acid derivatives include compounds such as norvaline, sarcosine, hydroxyproline, N-methyl-L-leucine, aminoisobutyric acid, statine, γ -carboxyglutamic acid, serine-O-phosphate, tyrosine-O-phosphate, tyrosine-O-sulfate, pyroglutamic acid and 4-(E)-butenyl-(R)-methyl-N-methyl-L-threonine. Other amino acid derivatives include the natural L- and unnatural D-amino acids in which side chain functionality is derivatized or protected with common protecting groups, e.g., tert-butoxycarbonyl (BOC). Numerous additional unnatural amino acids are well known and are available from commercial

sources, e.g., Aldrich Chemical Co., Milwaukee, WI or Sigma Chemical Co., St. Louis, MO. These materials include β -alanine and higher alkyl chain homologs, 1-amino-1-cyclopropanecarboxylic acid and higher alicyclic ring homologs, 5 2-amino-2-norbornenecarboxylic acid and isonipecotic acid. The techniques and methods used to synthesize, purify, and evaluate such compounds are well known in the art and are described, e.g., in *Synthetic Peptides: A Practical Approach*, Atherton, et al., Eds. (IRL Press 1989), which is incorporated herein by 10 reference.

Those of skill in the art will appreciate that compounds of the present invention may be derived from several alternative synthetic strategies. For example, reaction of N-tert-butoxycarbonyl-4-aminobenzyl isocyanate or N,N'-bis-tert-15 butoxycarbonyl-4-guanidinobenzyl isocyanate with an appropriate mono-protected diaminoalkylene or aminoalkanol provides a suitable intermediate which can be used to prepare compounds of the invention by methods analogous to those described above.

Those of skill in the art will also appreciate that 20 the compounds of the present invention may be derived from other compounds of the invention using well-known chemical transformations.

Those of skill in the art will also appreciate that 25 the compounds of the invention can be converted into the prodrug derivatives thereof. Suitable prodrugs can be represented by the formula $(T-X^1-X^2-X^3-X^4-X^5)_2Y$ in which each X^1 , X^2 , X^3 , X^4 and X^5 are as defined in the Summary of the Invention and T is $-NHR^4$, $-C(NHR^4)(NR^4)$ or $-NHC(NHR^4)(NHR^4)$, 30 wherein R^4 is $-C(O)OCH(R^5)OC(O)R^6$ and R^5 and R^6 independently (C_{1-10})alkyl or cyclo(C_{3-10})alkyl. Similarly, suitable prodrugs are represented by the formula R^7-Y-R^8 in which R^7 and R^8 are independently $T-X^1-X^2-X^3-X^4-X^5-$ in which T, X^1 , X^2 , X^3 , X^4 and X^5 are as defined above, with the proviso that R^7 and R^8 are not the same. Prodrugs of the compounds of the invention can be 35 prepared by methods known to those of ordinary skill in the art (see Saulnier et al., *Bioorganic and Medicinal Chemistry Letters*. 4:1985 (1994)). For example, appropriate prodrugs can be prepared by reacting a non-derivatized compound of the

invention with a suitable carbamylating agent (e.g., 1, 1-acyloxyalkylcarbonochloride, para-nitrophenyl carbonate and the like).

Compounds of this invention can, depending on the 5 nature of their functional groups, form addition salts with various inorganic and organic acids and bases. Typical inorganic acids include, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like. Typical organic acids include, e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.

10 Salts can also be formed from a carboxylic acid residue by treatment with alkali metals or alkali metal bases, such as alkali metal hydroxides and alkali metal alkoxides, or alkaline earth metals or alkaline earth metal bases, such as alkaline earth metal hydroxides and alkaline earth metal 15 alkoxides. In addition, salts can be formed from a carboxylic acid and an organic base, such as trimethylamine, diethylamine, ethanolamine, piperidine, isopropylamine, choline, caffeine, and the like.

The salts can be formed by conventional means, as by 20 reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water, which is then removed in vacuo or by freeze-drying or by exchanging the cations of an existing salt for another 25 cation on a suitable ion exchange resin.

III. In Vitro and In Vivo Testing

In vitro protocols for screening potential inhibitors as to their ability to inhibit tryptase are known in the art. 30 See, e.g., Sturzebecher et al. (1992) *Biol. Chem. Hoppe-Seyler* 373:1025-1030. Typically, these assays measure the tryptase-induced hydrolysis of peptide-based chromogenic

substances. Details of an exemplary procedure are described below.

In addition, the activity of the compounds of the present invention can be evaluated *in vivo* in one of the numerous animal models of asthma. See Larson, "Experimental Models of Reversible Airway Obstruction", in THE LUNG: SCIENTIFIC FOUNDATIONS, Crystal, West et al., eds., Raven Press, New York, 1991; Warner et al. (1990) Am. Rev. Respir. Dis. 141:253-257. An ideal animal model would duplicate the chief clinical and physiological features of human asthma, including: airway hyperresponsiveness to chemical mediators and physical stimuli; reversal of airway obstruction by drugs useful in human asthma (β -adrenergics, methyloxanthenes, corticosteroids, and the like); airway inflammation with infiltration of activated leukocytes; and chronic inflammatory degenerative changes, such as basement membrane thickening, smooth muscle hypertrophy, and epithelial damage. Species used as animal models include mice, rats, guinea pigs, rabbits, dogs, and sheep. All have some limitations, and the proper choice of animal model depends upon the question which is to be addressed.

The initial asthmatic response can be evaluated in guinea pigs, and dogs, and particularly, with a basenji-greyhound cross strain which develops nonspecific airway hyperresponsiveness to numerous nonallergenic substances, such as methacholine and citric acid. Certain selected sheep exhibit a dual response after antigen challenge with Ascaris proteins. In dual responding animals, the initial asthmatic response (IAR) is followed by a late asthmatic response (LAR) at 6-8 hours post-exposure. Hypersensitivity to the cholinergic agonist carbachol increases at 24 hours after antigen challenge in those animals which exhibit LAR.

The allergic sheep model (see below) was used to evaluate the potential antiasthmatic effects of the compounds of the present invention. Administration of compositions comprising the compounds of the present invention to allergic sheep in both oral and inhalant or aerosol formulations, prior to or following exposure to specific allergens demonstrates

that such compositions substantially lessen or abolish the late asthmatic response and consequent hyperresponsiveness.

The compounds of this invention are also useful for the treatment of other immunomediated inflammatory disorders in which tryptase activity contributes to the pathological condition. Such diseases include inflammatory diseases associated with mast cells, such as rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, inflammatory bowel disease, peptic ulcers and various skin conditions. Further, the compounds of the present invention can be used to treat syncytial viral infections.

The efficacy of the compounds of the present invention for the treatment of the vast majority of immunomediated inflammatory disorders can be evaluated by either *in vitro* or *in vivo* procedures. Thus, the anti-inflammatory efficacy of the compounds of the present invention can be demonstrated by assays well known in the art, for example, the Reversed Passive Arthus Reaction (RPAR)-PAW technique (see, e.g., Gangly et al. (1992) U.S. Patent No. 5,126,352). Assays for determining the therapeutic value of compounds in the treatment of various skin conditions, such as hyperproliferative skin disease, are well known in the art, for example, the Arachidonic Acid Mouse Ear Test. The compounds of the present invention can be evaluated for their antiulcer activity according to the procedures described in Chiu et al. (1984) *Archives Internationales de Pharmacodynamie et de Therapie* 270:128-140.

The efficacy of the compounds of the present invention in blocking cell fusion caused by a syncytial virus infection can be evaluated by the methods generally set forth in Tidwell, et al., *J. Med. Chem.* 26:294-298 (1983).

IV. In Vivo Administration

According to this invention, a therapeutically or pharmaceutically effective amount of a compound of the invention is administered to a patient suffering from an immunomediated inflammatory disorder. According to one

embodiment, the compositions of the present invention are useful for preventing or ameliorating asthma. In using the compositions of the present invention in a treatment of asthma, the compounds may be administered prophylactically prior to 5 exposure to allergen or other precipitating factor, or after such exposure. The compounds of the present invention are particularly useful in ameliorating the late-phase tissue destruction seen in both seasonal and perennial rhinitis. Another aspect of the present invention is directed to the 10 prevention and treatment of other immunomediated inflammatory disorders associated with mast cells such as urticaria and angioedema, and eczematous dermatitis (atopic dermatitis), and anaphylaxis, as well as hyperproliferative skin disease, peptic ulcers, and the like. In still a further embodiment, the 15 compounds of the present invention are used to treat syncytial viral infections, particularly infections of respiratory syncytial virus.

The compositions containing the compounds can be administered for therapeutic and/or prophylactic treatments.

20 In therapeutic applications, compositions are administered to a patient already suffering from a disease, as described above, in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as "therapeutically 25 effective amount or dose." Amounts effective for this use will depend on the severity and course of the disease, previous therapy, the patient's health status and response to the drugs, and the judgment of the treating physician.

In prophylactic applications, compositions containing 30 the compounds of the invention are administered to a patient susceptible to or otherwise at risk of a particular disease in an amount sufficient to prevent or ameliorate the onset of symptoms. Such an amount is defined to be a "prophylactically effective amount or dose." These can be administered orally or 35 by inhalation. In this use, the precise amounts again depend on the patient's state of health, weight, and the like.

Once improvement of the patient's conditions has occurred, a maintenance dose is administered if necessary.

Subsequently, the dosage or the frequency of administration, or both, can be reduced, as a function of the symptoms, to a level at which the improved condition is retained. When the symptoms have been alleviated to the desired level, treatment can cease.

5 Patients can, however, require intermittent treatment on a long-term basis upon any recurrence of the disease symptoms.

In general, a suitable effective dose of the compounds of the present invention will be in the range of 0.05 to 1000 milligram (mg) per recipient per day, preferably in the 10 range of 0.1 to 100 mg per day. The desired dosage is preferably presented in one, two, three, four or more subdoses administered at appropriate intervals throughout the day. These subdoses can be administered as unit dosage forms, for example, containing 0.01 to 1000 mg, preferably 0.01 to 100 mg 15 of active ingredient per unit dosage form.

The composition used in these therapies can be in a variety of forms. These include, for example, solid, semi-solid and liquid dosage forms, such as tablets, pills, powders, liquid solutions or suspensions, liposomes, injectable 20 and infusible solutions. Inhalable preparations, such as aerosols, are also included. Preferred formulations are those directed to oral, intranasal, topical and parenteral applications, but it will be appreciated that the preferred form will depend on the particular therapeutic application at hand. The methods for the formulation and preparation of 25 therapeutic compositions comprising the compounds of the invention are well known in the art and are described in, for example, REMINGTON'S PHARMACEUTICAL SCIENCES and THE MERCK INDEX 11th Ed., (Merck & Co. 1989).

30 While it is possible to administer the active ingredient of this invention alone, it is preferable to present it as part of a pharmaceutical formulation. The formulations of the present invention comprise at least one compound described herein in a therapeutically or pharmaceutically 35 effective dose together with a pharmacologically acceptable carrier. The pharmaceutical compositions will thus contain the compounds of the present invention in concentrations sufficient to deliver an appropriate dose. For example, where the

appropriate dose is 0.05 mg per day, the concentration of the compound of the invention in the pharmaceutical composition would be 0.5 mg per dose, where one dose per day is used. For inhalant or aerosol compositions, the concentration of the compounds of the present invention in the composition will generally depend upon the amount of the dose. Typical concentrations of the compounds of the present invention in inhalant or aerosol compositions would be from about 0.01 to about 30 mg/mL. The formulation may include other clinically useful compounds, such as β -adrenergics (e.g., albuterol, terbutaline, formoterol, fenoterol, and prenalone) and corticosteroids (e.g., beclomethasone, triamcinolone, flurisolide, and dexamethasone).

15 EXAMPLES

The following examples are provided merely for the purposes of illustration and are not to be construed in any way as limiting the scope of the present invention.

20 General Materials and Methods

The compounds described herein may be formed using techniques which are well known in the art, such as those techniques described in March, ADVANCED ORGANIC CHEMISTRY (Wiley 1992); Larock, COMPREHENSIVE ORGANIC TRANSFORMATIONS (VCH 1989); and Furniss, et al., VOGEL'S TEXTBOOK OF PRACTICAL ORGANIC CHEMISTRY 5th ed. (Longman 1989), each of which is incorporated herein by reference. It will be appreciated that the syntheses described herein may require one or more protection and deprotection steps. Accordingly, the use of appropriate protecting groups is necessarily implied by the processes contained herein, although not expressly illustrated. Such protection and deprotection steps may be accomplished by standard methods in addition to those described herein, such as those described in Green and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS (Wiley 1991), which is incorporated herein by reference.

Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for

example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, high-pressure liquid chromatography (HPLC), or a combination of these procedures. Specific illustrations of 5 suitable separation and isolation procedures can be had by reference to the examples hereinafter. However, other equivalent separation or isolation procedures can, of course, be used.

Nuclear magnetic resonance (NMR) spectra were 10 recorded on a General Electric "QE Plus" spectrometer (300 MHz). Infrared (IR) spectra were recorded on a Perkin-Elmer 1600 Fourier Transform IR (FTIR). Analytical HPLC was performed on a Ultrafast Microprotein Analyzer, Michrom BioResources, Inc. equipped with a PLRP or C₁₈ column, 1mm X 150mm. Preparative HPLC was performed on a Gilson LC using a 15 VYDAC 1x25 cm C₁₈ reverse phase (RP) column or a Waters Prep LC2000 system using a Vydac 5x25 cm C₁₈ RP column. Mass spectra (MS) were obtained on a Finnigan SSQ 710 with an ESI source by direct infusion or by HPLC MS (Ultrafast Microprotein 20 Analyzer, C₁₈ column 2mm X 150 mm).

Unless otherwise noted, all reagents and equipment were either prepared according to published procedures or were purchased from commercial sources, such as Aldrich Chemical Co. (Milwaukee, WI), Sigma Chemical Co. (St. Louis, MO) and ICN 25 Chemical Co. (Irvine, CA). The techniques used to perform the syntheses described below will be recognized by those of skill in the art as routine (see, e.g., March, Larock, or Furniss *supra*).

The following non-limiting Examples are intended to 30 illustrate the present invention. Those skilled in the art will recognize that certain variations and modifications can be practiced within the scope of the invention.

Example 1***trans-1,4-Cyclohexylenedimethylene bis(4-guanidinobenzylcarbamoylmethylaminocarboxylate) (Compound 1)***

5 The following example describes the preparation of a compound of the invention in which Z is guanidino, X¹ is X⁶-X⁷-X⁸, wherein n₆ is 0, n₈ is 1 and X⁷ is 1,4-phenylene, X² is -NHC(O)-, X³ is methylene, X⁴ is -NHC(O)O- and Y is *trans*-1,4cyclohexylenedimethylene.

10

trans-1,4-Cyclohexylenedimethylene bis(ethoxycarbonylmethylaminocarboxylate):

To a solution of *trans*-1,4-cyclohexanedimethanol (482mg, 3.34mmol.) in DMF (5mL) was added copper (I) chloride (99mg, 1.0mmol.) followed by ethyl isocyanatoacetate (800μL, 7.13mmol.) and the resulting suspension was allowed to stir at room temperature over twelve hours. Water (25mL) and dichloromethane (25mL) were added to the mixture and the aqueous phase extracted with additional dichloromethane (25mL). The combined organic layers were washed with water (2x 25mL) followed by saturated aqueous sodium chloride and dried over anhydrous magnesium sulfate. Filtration followed by concentration and drying in vacuo gave *trans*-1,4-cyclohexylenedimethylene bis[(glycine ethyl ester)-(N)-(α)-carboxylate] (1.19g, 89%) as a colorless solid.

¹H-NMR (300MHz, CDCl₃): 7.42 (tr, 2H), 4.15 (q, 4H), 3.75 (d, 4H), 3.70 (d, 4H), 1.80-1.60 (m, 4H), 1.55-1.40 (m, 2H), 1.15 (tr, 6H), 1.00-0.80 (m, 4H).

30

trans-1,4-Cyclohexylenedimethylene bis(ethoxycarbonylmethylaminocarboxylate):

To a solution of *trans*-1,4-cyclohexylene bis(N-methoxycarbonylglycine) (1.19g, 2.96mmol.) in tetrahydrofuran:methanol 3:1 (25mL) was added aqueous sodium hydroxide (1.6M, 6mL, 9.7mmol.) and the mixture was allowed to stir at room temperature over twelve hours. Concentration followed by acidification of the aqueous solution to pH=1 by dropwise addition of concentrated aqueous hydrochloric acid

gave a white precipitate. Filtration and drying in vacuo gave *trans*-1,4-cyclohexylene bis(N-methoxycarbonylglycine) as a colorless solid.

5 ¹H-NMR (300MHz, DMSO-d₆): 12.50 (s, 2H), 7.30 (tr, 2H), 3.75
 (d, 4H), 3.60 (d, 4H), 1.80-1.60 (m, 4H), 1.55-1.50 (m, 2H),
 1.00-0.80 (m, 4H).

10 *trans*-1,4-Cyclohexylenedimethylene bis(4-
 aminobenzylcarbamoylmethylaminocarboxylate):

15 *trans*-1,4-Cyclohexylene bis(N-methoxycarbonylglycine) (306mg, 0.88mmol.), hydroxybenztriazole hydrate (260mg, 1.92mmol.), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (360mg, 1.88mmol.) were dissolved in DMF (5mL) at 0°C and the resulting solution allowed to stir for one hour. 4-Aminobenzylamine (300μL, 2.64mmol.) was then added to the mixture which was subsequently allowed to warm to room temperature and stirred an additional twelve hours. Removal of DMF in vacuo followed by addition of water (25mL), filtration of the insoluble residue and drying in vacuo gave the desired aniline as a tan solid.

20 ¹H-NMR (300MHz, DMSO-d₆): 8.10 (tr, 2H), 7.20 (tr, 2H), 6.90
 (d, 4H), 6.50 (d, 4H), 5.40 (br s, 2H), 4.05 (d, 4H), 3.75 (d,
 4H), 3.55 (d, 4H), 1.80-1.60 (m, 4H), 1.50-1.40 (m, 2H),
 1.00-0.80 (m, 4H).

25 *trans*-1,4-Cyclohexylenedimethylene bis(4-
 guanidinobenzylcarbamoylmethylaminocarboxylate) (Compound 1):

30 *trans*-1,4-Cyclohexylenedimethylene bis(4-
 aminobenzylcarbamoylmethylaminocarboxylate) (87mg, 0.16mmol.) and cyanamide (0.5g, 11.9mmol.) were heated neat at 60°C to give a colorless solution followed by addition of hydrogen chloride (4M in dioxane, 160μL, 0.64mmol.). The resulting yellow liquid was stirred at 60°C an additional 1.5 hours followed by cooling to room temperature. Addition of ethyl ether (25mL) gave an insoluble yellow oil which was repeatedly washed with additional ethyl ether (3 x 25mL) to remove

residual cyanamide followed by drying in vacuo. The yellow oil was then taken into water (5mL) and purified by preparative reverse phase HPLC to give *trans*-1,4-cyclohexylenedimethylene bis(4-guanidinobenzylcarbamoylmethylaminocarboxylate) (Compound 1) bis-trifluoroacetate as a colorless solid.

¹H-NMR (300MHz, DMSO-d₆): 9.80 (s, 2H), 8.40 (tr, 2H), 7.20 (tr, 2H), 7.40 (s, 8H), 7.30 (d, 4H), 7.10 (d, 4H), 4.25 (d, 4H), 3.75 (d, 4H), 3.60 (d, 4H), 1.80-1.60 (m, 4H), 1.55-1.40 (m, 2H), 1.00-0.85 (m, 4H).

Electrospray LRMS: Calculated for C₃₀H₄₂N₁₀O₆: MH⁺: 639.7; MH₂⁺²/2: 320.4 Found: MH⁺: 639.1; MH₂⁺²/2: 319.8

Proceeding in a fashion analogous to the procedure described in Example 1 and substituting different starting materials the following compounds of the invention were prepared:

cis-1,5-cyclooctylene bis{4-[3-(1-amidinopiperid-4-yl)propionoyl]-1-piperazinecarboxylate} (Compound 5);
Electrospray LRMS: Calculated for C₃₆H₆₄N₈O₆: MH⁺: 731; Found: MH⁺: 730.7; cis-1,5-cyclooctylene bis {4-[3(4-amidinophenyl)propionoyl]-1-piperazinecarboxylate} (Compound 6); Electrospray LRMS: Calculated for C₃₈H₅₂N₈O₆: MH⁺: 716.9; Found: MH⁺: 717.9; and cis-1,5-cyclooctylene bis{[4-(1-amidinopiperid-4-ylacetyl)-1-piperazinecarboxylate]} (Compound 7); ¹H-NMR (300MHz, DMSO-d₆): 7.2(m, 8H), 4.6(s, 2H), 3.8(d, 8H), 3.4(m, 16H), 2.9(t, 4H), 2.3(s, 4H), 1.9(m, 2H), 1.6(m, 10H), 1.1(m, 4H).

30

Example 2

cis-1,5-Cyclooctylene bis[(N-(4-guanidinobenzylcarbamoylmethylaminocarboxylate) (Compound 2)

35 The following example describes the preparation of a compound of the invention in which Z is guanidino, X¹ is X⁶-X⁷-X⁸, wherein n₆ is 0, n₈ is 1 and X⁷ is 1,4-phenylene, X² is

$-NHC(O)-$, X^3 is methylene, X^4 is $-NHC(O)O-$ and γ is *cis*-1,5-cyclooctylene.

***cis*-1,5-Cyclooctylene**

5 **bis(ethoxycarbonylmethylaminocarboxylate):**

To a solution of *cis*-1,5-cyclooctanediol (514mg, 3.56mmol.) in DMF (5mL) was added copper (I) chloride (110mg, 1.1mmol.) followed by ethyl isocyanatoacetate (850 μ L, 7.6mmol.) and the resulting suspension was allowed to stir at room 10 temperature over twelve hours. Water (25mL) and dichloromethane (25mL) were added to the mixture and the aqueous phase extracted with additional dichloromethane (25mL). The combined organic layers were washed with water (2x 25mL) followed by saturated aqueous sodium chloride and dried over 15 anhydrous magnesium sulfate. Filtration followed by concentration and drying *in vacuo* gave *cis*-1,5-cyclooctylene bis(ethoxycarbonylmethylaminocarboxylate) as a colorless oil.

20 1H -NMR (300MHz, DMSO-d₆): 7.40 (tr, 2H), 4.60 (m, 2H), 4.05 (q, 4H), 3.65 (d, 4H), 1.80-1.40 (m, 12H), 1.15 (tr, 6H).

***Cis*-1,5-Cyclooctylene bis(N-methoxycarbonylglycine):**

To a solution of *cis*-1,5-cyclooctylene bis(ethoxycarbonylmethylaminocarboxylate) (1.26g, 3.1mmol.) in 25 tetrahydrofuran:methanol 3:1 (25mL) was added aqueous sodium hydroxide (1.6M, 6mL, 9.4mmol.) and the mixture was allowed to stir at room temperature over twelve hours. Concentration followed by acidification of the aqueous solution to pH=1 by dropwise addition of concentrated aqueous hydrochloric acid and extraction of the aqueous solution with ethyl acetate (3x 25mL) 30 gave the crude diacid. Drying the combined organic layers over anhydrous magnesium sulfate followed by filtration and concentration *in vacuo* gave *cis*-1,5-cyclooctylene bis(N-methoxycarbonylglycine) as a colorless oil.

35

1H -NMR (300MHz, DMSO-d₆): 7.25 (tr, 2H), 4.60 (m, 2H), 3.60 (d, 4H), 1.80-1.40 (m, 12H).

cis-1,5-Cyclooctylene

bis(4-guanidinobenzylcarbamoylmethylaminocarboxylate) (Compound 2):

cis-1,5-Cyclooctylene bis(N-methoxycarbonylglycine)

5 (64mg, 0.19mmol.) in dimethylformamide (3mL) was cooled to 0°C and hydroxybenztriazole (61mg, 0.45mmol.) was added followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (76mg, 0.40mmol.). The resulting mixture was stirred at 0°C over one hour then added by cannula to a slurry containing
10 4-guanidinophenylmethylamine bis-trifluoroacetate (290mg, 0.74mmol.) and triethylamine (500μL, 3.6mmol.) in dimethylformamide (2mL) cooled to 0°C. The mixture was then allowed to slowly warm to room temperature over twelve hours followed by concentration in vacuo. The residue was taken into
15 water (10mL) and the solution pH adjusted to 11-12 by dropwise addition of saturated aqueous sodium carbonate. The insoluble product was collected by decantation of the aqueous solution and the crude material taken back into aqueous solution by acidification to pH=1-2 with concentrated aqueous hydrochloric
20 acid. The material was then purified by preparative reverse phase HPLC to give *cis*-1,5-cyclooctylene
bis(4-guanidinobenzylcarbamoylmethylaminocarboxylate) (Compound 2) bis-trifluoroacetate as a colorless solid.

25 ¹H-NMR (300MHz, DMSO-d₆): 9.80 (s, 2H), 8.40 (tr, 2H), 7.40 (s, 8H), 7.25 (d, 4H), 7.20 (tr, 2H), 7.10 (d, 4H), 4.60 (m, 2H), 4.25 (d, 4H), 3.60 (d, 4H), 1.80-1.40 (m, 12H).

Electrospray LRMS: Calculated for C₃₀H₄₂N₁₀O₆: MH⁺: 639.7;
30 MH₂⁺²/2: 320.4
Found: MH⁺: 639.1; MH₂⁺²/2: 319.8

4-Guanidinobenzylamine bis-trifluoroacetate:

35 4-Aminobenzylamine (11.0g, 90mmol.) in dichloromethane (30mL) was cooled to 0°C and di-tert-butyl dicarbonate (18.65g, 85mmol.) was added to the solution and the mixture was allowed to slowly warm to room temperature over twelve hours. Subsequent filtration followed by washing the

dichloromethane solution with saturated aqueous ammonium chloride then with saturated aqueous sodium chloride, drying over anhydrous magnesium sulfate, filtration and concentration gave 4-amino-N-tert-butoxycarbonylbenzylamine as a yellow oil.

5 A methanol solution of the aniline was acidified with hydrogen chloride in dioxane (one equivalent) and the hydrochloride salt crystallized by addition of ethyl ether to the acidic solution. Filtration and drying *in vacuo* provided the hydrochloride salt as a yellow crystalline solid which was guanylated without further purification.

4-Amino-N-tert-butoxycarbonylbenzylamine hydrochloride (25.77g, 99.6mmol.) and cyanamide (55g, 1.3mol.) were heated neat at 65°C over 1.5 hours. The mixture was then cooled to room temperature and ether (250mL) was added. The 15 insoluble yellow oil was repeatedly washed with additional ethyl ether to remove traces of cyanamide and dried *in vacuo* to give 4-guanidino-N-tert-butoxycarbonylbenzylamine hydrochloride as an amorphous yellow material which was carried on without further purification.

20 4-Guanidino-N-tert-butoxycarbonylbenzylamine hydrochloride (14.4g, 48mmol.) was taken up into trifluoroacetic acid (35mL) and the resulting yellow solution stirred over 30 minutes. Concentration and drying *in vacuo* gave 4-guanidinobenzylamine bis-trifluoroacetate as a yellow 25 oil.

¹H-NMR (300MHz, DMSO-d₆): 10.25 (s, 1H), 8.40 (br s, 3H), 7.65 (br s, 4H), 7.50 (d, 2H), 7.25 (d, 2H), 4.00 (d, 2H).

30

Example 3

cis-1,5-Cyclooctylene bis[4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate] (Compound 3)

The following example describes the preparation of a compound of the invention in which Z is guanidino, X¹ is X⁶-X⁷-X⁸-, wherein n₆ is 0, n₈ is 1 and X⁷ is 1,4-phenylene, X² is -NHC(O)-, X³ is 1,4-piperazinylene, X⁴ is -C(O)O- and Y is cis-1,5-cyclooctylene.

Method A:

Cis-1,5-Cyclooctanediol bis-chloroformate:

Cis-1,5-Cyclooctanediol (3.05g, 21.2mmol.) was added to a solution of phosgene in toluene (1.9M, 28.0mL, 53mmol.) and the mixture was cooled to 0°C under a nitrogen atmosphere.

5 Pyridine (3.4mL, 43mmol.) was subsequently added by syringe and the resulting suspension was allowed to warm to room temperature over twelve hours. Dichloromethane (50mL) and water (50mL) were added to the reaction mixture and the organic layer washed with 0.1N aqueous hydrochloric acid (2x 25mL).

10 The dichloromethane solution was then dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo to give the crude chloroformate (3.7g, 65% yield) as a yellow crystalline solid. Further purification by silica gel flash chromatography using ethyl ether:hexanes 1:10 gives the pure

15 chloroformate as a colorless crystalline solid.

¹H-NMR (300MHz, CDCl₃): 5.00-4.85 (m, 2H), 2.20-1.60 (m, 12H).

cis-1,5-Cyclooctylene bis[4-(tert-butoxycarbonyl)-1-piperazinecarboxylate]:

20 cis-1,5-Cyclooctanediol bis-chloroformate (3.69g, 13.7mmol.) and diisopropylethylamine (7.2mL, 41mmol.) were taken into DMF (25mL) followed by addition of tert-butyl 1-piperazinecarboxylate (5.1g, 27.4mmol.) and the mixture was

25 allowed to stir at room temperature twelve hours. Concentration in vacuo to a semi-solid residue and addition of dichloromethane (50mL) and water (50mL) followed by washing the organic layer with 0.1N aqueous hydrochloric acid (2x 25mL) gave a crude solution of the desired carbamate. The

30 dichloromethane solution was then dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo to give cis-1,5-cyclooctylene bis[4-(tert-butoxycarbonyl)-1-piperazinecarboxylate] as an amorphous solid which was employed without further purification.

¹H-NMR (300MHz, CDCl₃): 4.80 (m, 2H), 3.40 (br s, 16H), 2.00-1.40 (m, 12H), 1.40 (s, 18H).

cis-1,5-Cyclooctylene bis(1-piperazinecarboxylate) bis-hydrochloride:

cis-1,5-Cyclooctylene bis[4-(tert-butoxycarbonyl)-1-piperazinecarboxylate] as obtained by the above procedure was 5 treated with trifluoroacetic acid (15mL) at room temperature for fifteen minutes followed by concentration in vacuo. The resulting oil was taken into water (30mL) and basified with an excess of solid potassium carbonate. The diamine was then extracted with dichloromethane (3x 25mL) and the combined 10 organic layers dried over anhydrous magnesium sulfate. Filtration followed by concentration provided *cis-1,5-cyclooctylene bis(1-piperazinecarboxylate)* as a colorless oil. The diamine was then taken up into methanol (15mL) and treated with hydrogen chloride in dioxane solution (4.0M, 5.3mL) 15 followed by addition of ethyl ether (250mL). The precipitate was collected by filtration and washed with additional ethyl ether followed by drying in vacuo to afford *cis-1,5-cyclooctylene bis(1-piperazinecarboxylate) bis-hydrochloride* as a colorless solid.

20

¹H-NMR (300MHz, DMSO-d₆): 9.50 (br s, 4H), 4.65 (m, 2H), 3.60 (s, 8H), 3.05 (s, 8H) 1.90-1.40 (m, 12H).

cis-1,5-Cyclooctylene bis[4-((p-tert-butoxycarbonylaminobenzyl)carbamoyl)-1-piperazinecarboxylate]:

cis-1,5-Cyclooctylene bis(1-piperazinecarboxylate) bis-hydrochloride (1.94g, 4.5mmol.) was taken into dichloromethane (75mL) followed by addition of diisopropylethylamine (2.0mL, 11.5mmol.). 4-Aminophenylmethyl 30 isocyanate tert-butylcarbamate (2.26g, 9.1mmol.) was subsequently added and the mixture was allowed to stir for two hours at room temperature. The dichloromethane solution was washed with 0.5N aqueous hydrochloric acid (2x 50mL) followed by drying over anhydrous magnesium sulfate and filtration. 35 Concentration in vacuo followed by silica gel flash chromatography with ethyl ether followed by ethyl acetate:ethanol 10:1 eluent afforded pure *cis-1,5-cyclooctylene*

bis[4-((p-tert-butoxycarbonylaminobenzyl)carbamoyl)-1-piperazinecarboxylate] (3.5g, 90% yield) as a colorless foam.

5 ¹H-NMR (300MHz, CDCl₃): 7.25 (dd AB, 8H), 6.70 (s, 2H), 5.00 (tr, 2H), 4.80 (m, 2H), 4.30 (d, 4H), 3.45-3.30 (m, 16H), 2.00-1.40 (m, 12H), 1.50 (s, 18H).

cis-1,5-Cyclooctylene bis[4-((p-aminobenzyl)carbamoyl)-1-piperazinecarboxylate]:

10 cis-1,5-Cyclooctylene bis[4-((p-tert-butoxycarbonylaminobenzyl)carbamoyl)-1-piperazinecarboxylate] (3.5g, 4.0mmol.) was treated with hydrogen chloride in dioxane (4.0M, 20mL) for 30 minutes at room temperature followed by dilution with ethyl ether (100mL). The solvent was carefully 15 decanted away from the hydrochloride salt precipitate and dried in vacuo to give cis-1,5-cyclooctylene bis[4-((p-aminobenzyl)carbamoyl)-1-piperazinecarboxylate] bis-hydrochloride as a hygroscopic tan solid which was employed without further purification.

20 ¹H-NMR (300MHz, DMSO-d₆): 10.25 (br s, 6H), 7.30 (dd AB, 8H), 7.15 (tr, 2H), 4.60 (m, 2H), 4.20 (d, 4H), 3.30 (s, 16H), 1.80-1.40 (m, 12H).

25 cis-1,5-Cyclooctylene bis[4-((4-guanidinobenzyl)carbamoyl)-1-piperazinecarboxylate] (Compound 3):

30 cis-1,5-Cyclooctylene bis[4-((p-aminobenzyl)carbamoyl)-1-piperazinecarboxylate] bis-hydrochloride as obtained by the above procedure was heated neat with excess cyanamide (8.0g, 190mmol.) at 60-65°C for 1.5 hours. The resulting yellow solution was cooled to room temperature and ethyl ether (250mL) was added. The insoluble residue was washed with additional ethyl ether (3x 100mL) and 35 the crude hydrochloride salt dried in vacuo. The amorphous material was then taken into water (40mL) and the suspension filtered using Millipore filter paper type GV (0.22μm). The resulting aqueous filtrate was purified by preparative reverse

phase HPLC followed by lyophilization to afford *cis*-1,5-cyclooctylene bis[4-((4-guanidinobenzyl)carbamoyl)-1-piperazinecarboxylate] (Compound 3) bis-hydrochloride as an off white solid.

5

¹H-NMR (300MHz, DMSO-d₆): 9.70 (s, 2H), 7.40 (s, 8H), 7.20 (dd AB, 8H), 7.15 (tr, 2H), 4.65 (m, 2H), 4.20 (d, 4H), 3.30 (s, 16H), 1.80-1.40 (m, 12H).

10 **Electrospray LRMS:** Calculated for C₃₆H₅₂N₁₂O₆: MH⁺: 749.9; MH₂⁺²/2: 375.5
Found: MH⁺: 749.9; MH₂⁺²/2: 375.3

4-(tert-Butoxycarbonylamino)benzylamine hydrochloride:

15 4-Aminobenzylamine (5.56g, 45.6mmol.) was taken up into water (45mL) and citric acid (9.63g, 50mmol.) was added to the solution. Di-tert-butyl dicarbonate (9.94g, 45.5mmol.) in dioxane (20mL) was added dropwise to the above solution and the mixture was allowed to stir at room temperature over 48 hours.
20 The yellow suspension was then filtered and the aqueous solution basified with excess solid sodium carbonate. Extraction of the aqueous solution with ethyl acetate (3x 35mL) followed by washing the combined organic layers with saturated aqueous sodium chloride and drying over anhydrous sodium sulfate afforded the crude benzylamine. Filtration and concentration in vacuo gave a white solid which was taken into methanol (30mL) and acidified with hydrogen chloride in dioxane (4M, 8.4mL, 33.6mmol.). Addition of ethyl ether (100mL) followed by filtration of the resulting suspension and drying
25 in vacuo provided 4-(tert-butoxycarbonylamino)benzylamine hydrochloride (7.2g, 61% yield) as a colorless solid.
30

¹H-NMR (300MHz, DMSO-d₆): 9.43 (s, 1H), 8.20 (br s, 3H), 7.40 (dd AB, 4H), 3.92 (m, 2H), 1.50 (s, 9H).

35

(tert-Butoxycarbonylamino)benzyl isocyanate:

4-(tert-Butoxycarbonylamino)benzylamine hydrochloride (3.39g, 13.1mmol.) was taken up into dichloromethane (120mL) at

0°C followed by addition of pyridine (4.3mL, 53mmol.) and triphosgene (1.3g, 4.4mmol.). The mixture was allowed to slowly warm to room temperature over twelve hours followed by addition of aqueous hydrochloric acid (0.5N, 100mL). The 5 organic layer was dried over anhydrous magnesium sulfate and filtered followed by concentration to afford (tert-Butoxycarbonylamino)benzyl isocyanate (2.7g, 84% yield) as a brown solid.

10 ¹H-NMR (300MHz, CDCl₃): 7.29 (dd AB, 4H), 6.55 (br s, 1H), 4.40 (s, 2H), 1.55 (s, 9H).

Method B:

15 **tert-Butyl 1-piperazinecarboxylate-4-carbonyl chloride:**
tert-Butyl 1-piperazinecarboxylate (321mg, 1.72mmol.) was taken up into dichloromethane (3.0mL) followed by addition of pyridine (210μL, 2.6mmol.) and the resulting solution cooled to 0°C. Triphosgene (255mg, 0.86mmol.) was subsequently added 20 and the reaction mixture was allowed to warm to room temperature over 30 minutes. Aqueous hydrochloric acid (0.1N, 5.0mL) and dichloromethane (5mL) were added to the mixture and the organic layer was dried over anhydrous magnesium sulfate. Filtration and concentration in vacuo gave tert-butyl 25 1-piperazinecarboxylate-4-carbonyl chloride (416mg, 97%) as a yellow crystalline solid.

30 ¹H-NMR (300MHz, CDCl₃): 3.70 (m, 2H), 3.60 (m, 2H), 3.50 (m, 4H), 1.50 (s, 9H).

1-[(4-Guanidinobenzyl)carbamoyl]piperazine bis-trifluoroacetate:
4-Guanidinobenzylamine bis-trifluoroacetate (380mg, 0.97mmol.) was taken up into DMF (2.0mL) followed by addition of diisopropylethylamine (700μL, 4.0mmol.). tert-Butyl 35 1-piperazinecarboxylate-4-carbamoyl chloride (241mg, 0.97mmol.) was subsequently added and the mixture was allowed to stir at room temperature over one hour. The resulting solution was concentrated in vacuo and taken up into water (5mL).

Filtration of the resulting suspension followed by basification of the aqueous solution with excess solid sodium carbonate gave an insoluble yellow oil which was separated from the aqueous phase by decantation. Drying in vacuo followed by treatment 5 with trifluoroacetic acid (5mL) for fifteen minutes afforded the crude phenylguanidine bis-trifluoroacetate as an orange oil upon concentration. The salt was then taken into water (5mL) and the material purified by preparative reverse phase HPLC and lyophilization to give 1-[(4-Guanidinobenzyl)carbamoyl] 10 piperazine bis-trifluoroacetate as a yellow amorphous solid.

¹H-NMR (300MHz, DMSO-d₆): 10.15 (s, 1H), 9.10 (br s, 2H), 7.65 (s, 4H), 7.40 (tr, 1H), 7.25 (dd AB, 4H), 4.25 (d, 2H), 3.55 (m, 4H), 3.10 (s, 4H).

15

Electrospray LRMS: Calculated for C₁₃H₂₀N₆O: MH⁺: 277.4; MH₂⁺²/2: 139.2

Found: MH⁺: 277.4; MH₂⁺²/2: 139.3

20 cis-1,5-Cyclooctylene bis[4-((4-guanidinobenzyl) carbamoyl)-1-piperazinecarboxylate] (Compound 3):

1-[(4-Guanidinobenzyl)carbamoyl]piperazine bis-trifluoroacetate (138mg, 0.27mmol.) was taken up into DMF (1.5mL) followed by addition of diisopropylethylamine (71.5μL, 25 0.4mmol.) and cis-1,5-cyclooctanediol bis-chloroformate (36.0mg, 0.14mmol.). The reaction mixture was allowed to stir at room temperature over twelve hours followed by concentration in vacuo. The amorphous residue was taken up into water (5mL) and the material purified by preparative reverse phase HPLC 30 followed by lyophilization to give cis-1,5-cyclooctylene bis[4-((4-guanidinobenzyl)carbamoyl)-1-piperazinecarboxylate] (Compound 3) as an off white solid.

Method C:

35

N-tert-butyl-N'-4-aminobenzylurea hydrochloride:

4-Aminobethylamine (50.34g, 0.412 mol) in dichloromethane (200 mL) was placed in a one liter 3-neck round bottom flask

fitted with mechanical stirring apparatus and the solution cooled to 0°C. di-tert-Butyl dicarbonate (89.9g, 0.412 mol) in dichloromethane (200 mL) was added dropwise to the solution over 30 minutes and the resulting suspension was allowed to
5 stir at 0°C an additional two hours at which point a nearly homogeneous solution was obtained. The dichloromethane solution was subsequently washed with aqueous sodium hydroxide (1.0M, 500 mL) followed by water (500 mL) and the organic phase dried over anhydrous magnesium sulfate. Filtration followed by
10 concentration in vacuo gave 4-amino-N-tert-butylcarbamoylbenzylamine as a yellow oil. The aniline was then taken into ethyl ether:methanol (2:1, 225 mL) and the solution cooled to 0°C. Acidification with hydrogen chloride in dioxane (4.0M, 115 mL, 0.412 mol) followed by addition of
15 ethyl ether (200 mL) gave a thick pale yellow precipitate. Filtration followed by washing with additional ethyl ether (500 mL) and drying in vacuo provided N-tert-butyl-N'-4-aminobenzylurea hydrochloride (100.23g, 94% yield) as a pale yellow solid which was used without further purification.

20

¹H-NMR (300 MHz, DMSO-d₆): 10.40-10.20 (br s, 3H) 7.40 (tr, 1H), 7.30 (s, 4H), 4.10 (d, 2H), 1.40 (s, 9H).

N-tert-butyl-N-4-guanidinobenzylurea:

25 Cyanamide (100g, 2.4 mol) was placed in a 500 mL round bottom flask and heated to 60-65°C until the material completely melted. N-tert-butyl-N'-4-aminobenzylurea hydrochloride, (25.3g, 97.8 mmol) was then added directly to the liquid cyanamide and the resulting yellow solution was
30 stirred at 60-65°C an additional two hours. Water (100 mL) was subsequently added to the solution followed by cooling to room temperature. The aqueous solution was washed with ethyl ether (1L) followed by back extraction of the organic phase with water (2x, 100 mL). The combined aqueous layers were again
35 washed with ethyl ether (500 mL) and the aqueous solution cooled in an ice water bath followed by basification with aqueous sodium hydroxide (10M, 100 mL). The resulting insoluble oil slowly crystallized and was collected by

filtration. The material then was washed with water and dried in vacuo to give *N*-tert-butyl-*N*-4-guanidinobenzylurea (18.3g, 70.8%) as a colorless crystalline solid.

5 ¹H-NMR (300 MHz, DMSO-d₆): 9.70 (s, 1H), 7.42 (tr, 1H), 7.40 (s, 4H), 7.25 (d, 2H), 7.15 (d, 2H), 4.10 (d, 2H), 1.40 (s, 9H).

tert-Butyl 4-chlorocarbonyl-1-piperazinecarboxylate:

10 Triphosgene (25g, 84.2 mmol) was taken into dichloromethane (200 mL) and the resulting solution cooled to 0°C. A solution of tert-butyl 1-piperazinecarboxylate (40g, 214.8 mmol) and pyridine (35 mL, 432.7 mmol) in dichloromethane (100 mL) was then added dropwise to the triphosgene solution 15 and the reaction mixture was allowed to warm to room temperature over 30 minutes. The mixture was then quenched by addition of aqueous hydrochloric acid (0.1N, 200 mL) and the aqueous phase washed with dichloromethane (50 mL) followed by drying the combined organic layers over anhydrous magnesium sulfate. Filtration and concentration in vacuo gave tert-butyl 20 4-chlorocarbonyl-1-piperazinecarboxylate (45.6g, 85%) as a yellow solid which may be used without further purification. The material can be purified further by crystallization from ethyl ether/hexane.

25 ¹H-NMR (300 MHz, CDCl₃): 3.70 (m, 2H), 3.60 (m, 2H), 3.50 (m, 4H), 1.50 (s, 9H).

tert-Butyl 4-guanidinobenzylcarbamoyl-1-piperazinecarboxylate
30 trifluoroacetate:

35 *N*-tert-butyl-*N*-4-guanidinobenzylurea (41.77g, 0.158 mol) was treated with trifluoroacetic acid (100 mL) for 30 minutes at room temperature. The resulting nearly colorless liquid was concentrated in vacuo at 45°C then triturated with ethyl ether (3x 400 mL) and dried in vacuo to a colorless foam. Methanol (200 mL) was added to the residue followed by diisopropylethylamine (55 mL, 0.32 mol., amount based on estimated excess TFA present) and the solution was cooled to

0°C. *tert*-Butyl 1-piperazinecarboxylate-4-carbamoyl chloride (39.3g, 0.158 mol) in dichloromethane (120 mL) was added to the reaction mixture followed by additional diisopropylethylamine (30 mL). The reaction mixture was allowed to warm to room

5 temperature and stirred for an additional 12 hours.

Concentration *in vacuo* to an orange oil followed by addition of water (200 mL) gave a thick precipitate which was collected by filtration. The crude guanidine TFA salt was recrystallized from acetonitrile/ether to give *tert*-butyl 4-

10 guanidinobenzylcarbamoyl-1-piperazinecarboxylate trifluoroacetate (62.0g, 80%) as a pale yellow solid.

¹H-NMR (300 MHz, DMSO-d₆): 10.15 (s, 1H), 9.10 (br s, 2H), 7.65 (s, 4H), 7.40 (tr, 1H), 7.25 (dd AB, 4H), 4.25 (d, 2H), 3.55 (m, 4H), 3.10 (s, 4H).

Electrospray LRMS: Calculated for C₁₃H₂₀N₆O: MH⁺: 277.4; MH₂⁺²/2: 139.2 Found: MH⁺: 277.4; MH₂⁺²/2: 139.3.

20

cis-1,5-cyclooctylene bis[4-4-guanidinobenzylaminecarbonyl]-1-piperazinecarboxylate (Compound 3)

tert-Butyl 4-guanidinobenzylcarbamoyl-1-piperazinecarboxylate trifluoroacetate (50g, 0.102 mol) was

25 treated with trifluoroacetic acid (50 mL) at room temperature for 15 minutes to give a homogeneous solution. The bulk of TFA was removed *in vacuo* giving a water soluble amorphous residue.

This material is then taken into water (100 mL) and the pH adjusted to 7.0-7.5 by careful addition of 10M aqueous sodium

30 hydroxide. *cis*-1,5-cyclooctylene bis-chloroformate (13.5g, 0.05 mol) in THF (75 mL) is added to the above aqueous solution and the mixture is stirred at room temperature. The pH of this mixture is monitored using a standard laboratory pH meter and continually readjusted to the 7.0-8.0 range by addition of 10M

35 aqueous sodium hydroxide as needed. After the pH is stabilized (approximately one hour) the reaction is determined to be complete by reverse phase analytical HPLC. Ethyl ether (50 mL) is then added to the nearly homogeneous solution followed by

basification of the biphasic mixture with an excess of 10M aqueous sodium hydroxide giving a white suspension of free base arylguanidine. This suspension is concentrated on the rotary evaporator to remove the bulk of THF and the fine precipitate collected by filtration. The paste consistency solid then was washed once with water and dried *in vacuo* to give *cis*-1,5-cyclooctylene bis[4-4-guanidinobenzylaminecarbonyl)-1-piperazinecarboxylate (31g, 81%) as a white solid (purity>97% as determined by HPLC). The free base was dissolved in aqueous hydrochloric acid and filtered to remove traces of insoluble residue and lyophilization to give *cis*-1,5-cyclooctylene bis[4-4-guanidinobenzylaminecarbonyl)-1-piperazinecarboxylate hydrochloride.

15 ¹H-NMR (hydrochloride salt) (300 MHz, DMSO-d₆): 9.70 (s, 2H), 7.40 (s, 8H), 7.20 (dd AB, 8H), 7.15 (tr, 2H), 4.65 (m, 2H), 4.20 (d, 4H), 3.30 (s, 16H), 1.80-1.40 (m, 12H).

20 Electrospray LRMS (hydrochloride salt): Calculated for C₃₆H₅₂N₁₂O₆: MH⁺: 749.9; MH₂⁺²/2: 375.5
Found: MH⁺: 749.9; MH₂⁺²/2: 375.3.

25 Proceeding in a fashion analogous to the procedure described in Example 3, Method A, and substituting different starting materials, the following compounds of the invention were prepared:

30 *cis*-1,5-cyclooctylene bis{4-[2-(1-amidinopiperid-4-yl)ethylcarbamoyl]-1-piperazinecarboxylate} (Compound 8); ¹H-NMR (300MHz, DMSO-d₆): 7.4(s, 8H), 6.6(s, 2H), 4.6(s, 2H), 3.8(d, 4H), 3.6(s, 8H), 3.3(s, 14H), 3.0 (m, 20H) 1.0(m, 4H);
35 *cis*-1,5-cyclooctylene bis[4-(trans-4-aminomethylcyclohexylcarbonyl)-1-piperazinecarboxylate] (Compound 9); Electrospray LRMS: Calculated for C₃₈H₆₂N₆O₆: MH⁺: 647.9 Found: MH⁺ 648.1;
 cis-1,5-cyclooctylene bis [4-(4-guanidinophenylacetyl)-1-piperazinecarboxylate] (Compound 10); Electrospray LRMS: Calculated for C₃₆H₅₀N₁₀O₆; MH⁺; 718.9; Found: MH⁺: 717.3;

cis-1,5-cyclooctylene bis[4-[3-(4-guanidinophenyl)propionyl]-1-piperazinecarboxylate] (Compound 11); **Electrospray LRMS:** Calculated for $C_{38}H_{54}N_{10}O_6$: MH^+ : 746.9; Found: MH^+ : 745.5;

5 *cis*-1,5-cyclooctylene bis [4-(*trans*-4-aminomethylcyclohexylmethylcarbamoyl)-1-(perhydro-7H-1,4-diazepine)carboxylate] (Compound 12); **Electrospray LRMS:** Calculated for $C_{38}H_{68}N_8O_6$: MH^+ : 734; $MH_2^{+2}/2$: 367.5; Found: $MH_2^{+2}/2$: 367.7;

10 *cis*-1,5-cyclooctylene bis[4-(4-aminomethylbenzylcarbamoyl)-1-piperazinecarboxylate] (Compound 13); **Electrospray LRMS:** Calculated for $C_{36}H_{52}N_8O_6$: MH^+ : 693.9; Found: MH^+ : 693.5;

15 *cis*-1,5-cyclooctylene bis {4-[4-(2-aminoethyl)benzylcarbamoyl]-1-piperazinecarboxylate} (Compound 14); 1H -NMR (300MHz, DMSO- d_6): 7.34, 7.15(d, 8H), 4.64(bt, 4H), 4.15(m, 2H), 3.92(d, 4H), 3.54(m, 4H), 3.25(appd, 16H), 1.73-1.47(m, 12H); **Electrospray LRMS:** Calculated for $C_{38}H_{56}N_8O_6$: MH^+ : 721; Found: MH^+ : 721;

20 *cis*-1,5-cyclooctylene [4-(4-aminomethylbicyclo[2.2.2]oct-1-ylmethylcarbamoyl)-1-piperazinecarboxylate] (Compound 15); 1H -NMR (300MHz, DMSO- d_6): 4.18(m, 2H), 3.40(m, 4H), 3.21(d, 16H), 2.8(d, 4H), 1.75-1.39(m, 36H);

25 *cis*-1,5-cyclooctylene bis{4-[4-(2-aminoethyl)phenylacetyl]-1-piperazinecarboxylate}] (Compound 16); 1H -NMR (300MHz, DMSO- d_6): 7.13, 6.93(d, 8H), 5.8(d, 4H), 3.68(m, 4H), 3.56, 3.39(d, 16H), 4.0(m, 2H), 2.69(t, 4H), 2.69(t, 4H), 1.82-1.50(m, 12H); **Electrospray LRMS:** Calculated for $C_{38}H_{54}N_6O_6$: MH^+ : 691; Found: MH^+ : 691;

30 *cis*-1,5-cyclooctylene bis{4-[4-(2-aminoethyl)benzoyl]-1-piperazinecarboxylate} (Compound 17); **Electrospray LRMS:** Calculated for $C_{36}H_{50}N_6O_6$: MH^+ : 662.8; Found: MH^+ : 664;

35 *cis*-1,5-cyclooctylene bis {4-[4-(1-aminoprop-2-yl)benzoyl]-1-piperazinecarboxylate} (Compound 18); 1H -NMR (300MHz, DMSO- d_6): 7.33(s, 8H), 4.6(m, 2H), 3.35-3.06(m, 18H), 2.97(m, 4H), 1.73-1.5(m, 12H), 1.22(d, 6H), 1.82-1.50(m, 12H); **Electrospray LRMS:** Calculated for $C_{36}H_{54}N_6O_6$: MH^+ : 691; Found: MH^+ : 692;

40 *cis*-1,5-cyclooctylene bis{4-[4-(2-aminoethyl)piperid-1-yl]-1-piperazinecarboxylate} (Compound 19); 1H -NMR (300MHz, DMSO- d_6):

3.62(d, 8H), 3.42, 3.19(s, 16H), 2.97(t, 4H), 2.82(t, 4H),
1.77-1.55(m, 24H), 1.13(m, 4H); **Electrospray LRMS:** Calculated
for C₃₄H₆₀N₈O₆: MH⁺: 676.9; Found: MH⁺: 677;
cis-1,5-cyclooctylene bis{4-[*trans*-4-(2-
5 aminoethyl)cyclohexylacetyl]-1-piperazinecarboxylate}
(Compound 20); ¹H-NMR (300MHz, DMSO-d₆): 3.52(m, 16H),
2.97(t, 4H), 2.39(d, 4H), 1.81-1.5(m, 34H), 1.32(m, 6H), 0.99(m,
2H); **Electrospray LRMS:** Calculated for C₃₈H₆₄N₆O₆: MH⁺: 703;
Found: MH⁺: 703;

10 *trans*-1,4-cyclohexylene bis[4-(4-guanidinobenzylcarbamoyl)-1-
piperazinecarboxaldehyde] (Compound 21); **Electrospray LRMS:**
Calculated for C₃₂H₄₄N₁₂O₄: MH⁺: 688.8; Found: MH⁺: 689; and
cis-1,5-cyclooctylene bis {4-[4-(2-
aminoethyl)cyclohexylcarbonyl]-1-piperazinecarboxylate}
15 (Compound 22); ¹H-NMR (300MHz, DMSO-d₆): 3.56, 3.49(d, 16H),
2.96(t, 4H), 1.77(m, 20H), 1.51(m, 6H), 1.33(m, 6H), 1.01(m, 4H);
Electrospray LRMS: Calculated for C₃₆H₆₂N₆O₆: MH⁺: 674.9; Found:
MH⁺ 675.

20 Proceeding in a fashion analogous to the procedure
described in Example 3, Method B, and substituting different
starting materials, the following compounds of the invention
were prepared:

25 *trans*-1,4-cyclohexylenedimethylene bis{4-
[4(aminomethyl)piperid-1-ylcarbonylaminoethyl]-1-
piperidinecarboxylate} (Compound 23); ¹H-NMR (300MHz, DMSO-d₆):
8.0(s, 4H), 6.5(s, 2H), 4.5(m, 8H), 3.9(m, 4H), 3.8(m, 2H),
2.8(s, 2H), 2.6(m, 16H), 1.6(m, 16H), 1.0(m, 10H);
cis-1,5-cyclooctylene bis[4-(4-amidinophenylacetyl)-1-
piperazinecarboxylate] (Compound 24); **Electrospray LRMS:**
30 Calculated for C₃₄H₄₈N₈O₆: MH⁺: 688.8; Found: MH⁺: 689.6;
cis-1,5-cyclooctylene bis{4-[4-(aminomethyl)piperid-1-
ylcarbonylamino]butylaminocarboxylate} (Compound 25); ¹H-NMR
(300MHz, DMSO-d₆): 8.1(s, 6H), 7.0(s, 2H), 4.6(s, 2H), 4.2(m,
12H), 3.9(d, 4H), 2.9(m, 8H), 2.6(m, 8H), 1.6(m, 20H), 1.3(s,
35 6H), 1.0(m, 4H), **Electrospray LRMS:** Calculated for C₃₁H₆₄N₈O₆:
MH⁺: 652.9; Found: MH⁺: 653.7;
cis-1,5-cyclooctylene bis{4-[4-(aminomethyl)piperid-1-
ylcarbonylaminoethyl]-1-piperidinecarboxylate} (Compound 26);

¹H-NMR (300MHz, DMSO-d₆): 8.1(s, 6H), 6.5(s, 2H), 4.6(s, 4H), 4.0(m, 24H), 2.9(d, 4H), 2.6(m, 12H), 1.6(m, 20H), 0.9(m, 14H);

Electrospray LRMS: Calculated for C₃₄H₆₄N₈O₆: MH⁺: 705; Found: MH⁺: 706.6;

5 **cis-1,5-cyclooctylene bis[4-(1-amidinopiperid-4-ylmethylcarbamoyl)-1-piperazinecarboxylate]** (Compound 27); ¹H-NMR (300-MHz, DMSO-d₆): 7.2(s, 8H), 6.6(m, 2H), 4.6(m, 4H), 3.8(d, 6H), 3.4(m, 31H), 2.9(m, 8H), 1.7(m, 16H), 1.1(m, 4H);

10 **cis-1,5-cyclooctylene bis[4-(4-amidinobenzylcarbamoyl)-1-piperazinecarboxylate]** (Compound 28); ¹H-NMR (300MHz, DMSO-d₆): 9.4(s, 4H), 7.8(d, 4H), 7.6(d, 4H), 7.4(m, 2H), 4.8(m, 2H), 4.4(m, 4H), 3.4(m, 40H), 1.8(m, 10H);

15 **trans-2,6-(4,8-dioxabicyclo[3.3.0]octylene) bis[4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate]** (Compound 29); **Electrospray LRMS:** Calculated for C₃₄H₄₆N₁₂O₈: MH⁺: 751.8; MH₂⁺²/2: 376.4; Found: MH⁺: 751.2; MH₂⁺²/2: 376.4;

20 **trans-2,3-bicyclo[2.2.2]oct-5-enylenedimethylene bis[4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate]** (Compound 30); **Electrospray LRMS:** Calculated for C₃₈H₅₂N₁₂O₆: MH⁺: 773.9; MH₂⁺²/2: 387.5; Found: MH⁺: 773.2; MH₂⁺²/2: 387.2;

25 **cis-1,5-tetracyclo[3.3.1.1^{3,7}]decylenedimethylene bis[4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate]** (Compound 31); **Electrospray LRMS:** Calculated for C₄₀H₅₈N₁₂O₄: MH⁺: 768; MH₂⁺²/2: 384.5; Found: MH⁺: 769.4; MH₂⁺²/2: 385.4; and **cis-1,5-cyclooctylene bis[4-(4-amidinobenzoylaminomethyl)-1-piperidinecarboxylate]** (Compound 44); ¹H-NMR (300MHz, DMSO-d₆): 9.43 (s, 2H), 9.16 (s, 2H), 8.77 (t, 1H), 8.00 (d, 2H), 7.86 (d, 2H), 4.61 (br s, 1H), 3.91(br d, 2H), 3.14 (br s, 2H), 2.69 (br s, 2H), 1.79-1.54 (m, 8H), 1.51-1.42 (m, 1H), 0.99 (q, 2H); **Electrospray LRMS:** Calculated for C₃₈H₅₄N₈O₆: MH⁺: 716.9; MH₂⁺²/2: 358.5; Found: MH⁺: 717.5; MH₂⁺²/2: 359.5; **cis-1,5-cyclooctylene bis[4-(4-amidinopiperid-1-ylcarbonylaminomethyl)-1-piperidinecarboxylate]** (Compound 45); ¹H-NMR (300MHz, DMSO-d₆): 8.8 (d, 4H), 6.57 (s, 1H), 4.61 (s, 1H), 4.06 (d, 2H), 3.9 (d, 2H), 2.84 (br s, 2H), 2.73-2.5 (m, 4H), 1.77-1.4 (m, 10H), 0.89 (q, 2H); **Electrospray LRMS:** Calculated for C₃₆H₆₆N₁₀O₆: MH⁺: 732.9; MH₂⁺²/2: 366.9; Found: MH⁺: 731.6; MH₂⁺²/2: 366.5; and **cis-1,5-tetracyclo[3.3.1.1^{3,7}]decylenedimethylene bis[4-(4-**

guanidinobenzylcarbamoyl)-1-piperazinecarboxaldehyde] (Compound 32); Electrospray LRMS: Calculated for $C_{40}H_{58}N_{12}O_6$: MH^+ : 801.9; Found: MH^+ : 802.1; 1,2-cyclohexylene bis[4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxaldehyde] (Compound 46); Electrospray LRMS: Calculated for $C_{34}H_{48}N_{12}O_4$: $MH^{+2}/2$: 345.7; Found: $MH^{+2}/2$: 345.3; 1,4-bicyclo{2.2.2}octylenedimethylene bis[4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate] (Compound 47); Electrospray LRMS: Calculated for $C_{38}H_{54}N_{12}O_6$: $MH^{+2}/2$: 388.3; Found: MH^{+2} : 388.3; cis-1,5-cyclooctylen bis[4-(4-guanidinophenylcarbonylaminomethyl)-1-piperidinecarboxylate] (Compound 48); Electrospray LRMS: Calculated for $C_{38}H_{54}N_{10}O_6$: MH^{+2} : 374.5; Found: $MH^{+2}/2$: 374.6; and cis-1,4-cyclohexylenedimethylene bis[4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate] (Compound 49); Electrospray LRMS: Calculated for $C_{36}H_{52}N_{12}O_6$: $MH^{+2}/2$: 375.4; Found: $MH^{+2}/2$: 375.1.

Example 4

20

cis-1,5-Cyclooctylen bis[4-((trans-4-aminomethylcyclohexylene methylene)carbamoyl)-1-piperazinecarboxylate] (Compound 4)

The following example describes the preparation of a compound if this invention in which Z is amino, X^1 is $-X^6-X^7-X^8-$ (wherein n_6 is 1, X^7 is trans-1,4-cyclohexylene), X^2 is $-NHC(O)-$, X^3 is 1,4-piperazinylene, X^4 is $-C(O)O-$ and Y is cis-1,5-cyclooctylene.

trans-4-(Aminomethyl)cyclohexanemethanol hydrochloride:

30 A 1.0 M solution of borane in tetrahydrofuran (250mL, 260mmol.) was added slowly dropwise to a suspension of trans-4-(aminomethyl)cyclohexanecarboxylic acid (10.0g, 64.0mmol.) in tetrahydrofuran (250 mL). Gas evolution was observed. The reaction mixture was heated at reflux for 14 hours. The resulting solution was cooled to 0°C and carefully treated dropwise with 1 N methanolic hydrochloric acid (250 mL). Gas evolution was observed. The white suspension obtained was stirred for 1 hour at 23°C and subsequently

concentrated. Methanol was added to the residue and the suspension was concentrated. This procedure was repeated twice to give trans-4-(Aminomethyl)cyclohexanemethanol hydrochloride (10.6 g, 93% yield) as a white solid.

5

¹H NMR (CD₃OD): 3.38 (d, 2H), 2.71 (d, 2H), 1.88 (d, 4H), 1.48 (m, 2H), 1.01 (m, 2H)

N-tert-Butoxycarbonyl-trans-4-(aminomethyl)cyclohexanemethanol:

10 Sodium carbonate (1.33g, 12.4mmol.) was added to a solution of trans-4-(aminomethyl)cyclohexanemethanol hydrochloride (1.5g, 8.3mmol.) in 1:1 dioxane:water (40mL). Di-tert-butyl dicarbonate (2.0g, 9.13mmol.) was added to the reaction mixture at 0°C. The reaction mixture was stirred at room temperature for 5 hours then partitioned between 10% methanol in dichloromethane and water. The organic layer was dried over anhydrous sodium sulfate and concentrated.

15 N-tert-Butoxycarbonyl-trans-4-(aminomethyl)cyclohexanemethanol (1.97g, 98% yield) was obtained as a white solid.

20

¹H NMR (CDCl₃): 4.58 (br, 1H), 3.44 (d, 2H), 2.95 (tr, 2H), 1.81 (m, 4H), 1.54 (m, 2H), 1.44 (s, 9H), 0.92 (tr, 4H)

25 **N-tert-Butoxycarbonyl-trans-4-(aminomethyl)cyclohexanemethyl tosylate:**

30 p-Toluenesulfonyl chloride (3.3 g, 17.0 mmol) was added to a solution of N-tert-butoxycarbonyl-trans-4-(aminomethyl)cyclohexanemethanol (3.5 g, 14.0 mmol) in pyridine (20 mL) containing 4 Å sieves and the reaction mixture was stirred at 23°C for 23.5 hours. The resulting white suspension was concentrated and the residue obtained partitioned between dichloromethane and 0.05 N hydrochloric acid. The organic layer was dried over sodium sulfate and concentrated. Crude

35 N-tert-butoxycarbonyl-trans-4-(aminomethyl)cyclohexanemethyl tosylate (5.73g) was obtained as a yellow solid.

¹H NMR (CDCl₃): 7.78 (d, 2H), 7.34 (d, 2H), 4.56 (br, 1H), 3.82 (d, 2H), 2.94 (tr, 2H), 2.48 (s, 3H), 1.74 (d, 4H), 1.64 (m, 2H), 1.48 (s, 9H), 0.91 (tr, 4H)

5 **N-tert-Butoxycarbonyl-trans-4-(aminomethyl)cyclohexanemethyl azide:**

Sodium azide (4.7g, 70.0mmol.) was added to a solution of N-tert-butoxycarbonyl-trans-4-(aminomethyl)cyclohexanemethyl tosylate (5.73g, 14.0mmol.) in DMF (50 mL) containing 4 Å sieves and the resulting suspension stirred at 23°C for 190 hours followed by concentration. The residue obtained was partitioned between dichloromethane and water. The organic layer was dried over anhydrous sodium sulfate and concentrated. N-tert-Butoxycarbonyl-trans-4-(aminomethyl)cyclohexanemethyl azide (3.22g, 86% yield) was obtained as a yellow oil.

¹H NMR (CDCl₃): 3.14 (d, 2H), 2.99 (tr, 2H), 1.82 (tr, 4H), 1.51 (m, 2H), 1.48 (s, 9H), 0.99 (m, 4H)

20 **N-tert-Butoxycarbonyl-trans-1,4-cyclohexane bis(methylamine) hydrochloride:**

Ethanol (40 mL) was added to N-tert-butoxycarbonyl-trans-4-(aminomethyl)cyclohexanemethyl azide (1.79g, 6.67mmol.) and 5% palladium on carbon (270mg, 0.15 wt. %) under nitrogen. The reaction mixture was stirred under hydrogen at atmospheric pressure for 6 hours at 23°C. The black suspension was filtered and the filtrate concentrated to give N-tert-butoxycarbonyl-trans-1,4-cyclohexane bis(methylamine) as a yellow oil. The crude amine was taken up into methanol (2.0mL) followed by addition of hydrogen chloride in dioxane (4.0M, 2.0mL, 8.0mmol.) and ethyl ether (25mL). The resulting precipitate was collected by filtration to give N-tert-butoxycarbonyl-trans-1,4-cyclohexanebis(methylamine) hydrochloride (1.42g, 76% yield) as a colorless solid.

35

¹H NMR (D₂O): 3.00-2.80 (m, 4H), 1.90-1.70 (m, 4H), 1.70-1.50 (m, 2H), 1.40 (s, 9H), 1.10-0.90 (m, 4H).

Electrospray LRMS: Calculated for $C_{13}H_{27}N_2O_2$ (MH^+): 243
Found: 243

5 **N-tert-Butoxycarbonyl-trans-4-(aminomethyl)cyclohexanemethyl isocyanate:**

10 **N-tert-Butoxycarbonyl-trans-1,4-cyclohexane bis(methylamine) hydrochloride** (1.45g, 5.2mmol.) was taken up into dichloromethane (25mL) followed by addition of pyridine (1.75mL, 21mmol.) and the mixture was cooled to 0°C.
Triphosgene (617mg, 2.1mmol.) was subsequently added to the above solution and the mixture was allowed to slowly warm to room temperature over 2 hours. The organic solution was washed with 0.1N aqueous hydrochloric acid (2x 25mL) followed by drying over anhydrous magnesium sulfate and filtration.

15 Concentration gave

N-tert-butoxycarbonyl-trans-4-(aminomethyl)cyclohexanemethyl isocyanate (1.38g, 99% yield) as a yellow crystalline solid.

20 1H NMR ($CDCl_3$): 4.60 (br s, 1H), 3.15 (d, 2H), 2.95 (tr, 2H), 1.85-1.75 (m, 4H), 1.50-1.40 (m, 2H), 1.45 (s, 9H), 1.05-0.90 (m, 4H).

25 **cis-1,5-Cyclooctylene bis[4-((trans-4-tert-butoxycarbonylaminomethylcyclohexenemethylene)carbamoyl)-1-piperazinecarboxylate]:**

30 **cis-1,5-Cyclooctylene bis(1-piperazinecarboxylate)** bis-hydrochloride (229.7mg, 0.53mmol.) and diisopropylethylamine (200 μ L, 2.3mmol.) were dissolved in DMF (4.0mL) and the mixture cooled to 0°C.
N-tert-Butoxycarbonyl-trans-4-(aminomethyl)-cyclohexanemethyl isocyanate (285mg, 1.06mmol.) was subsequently added and the mixture was allowed to warm to room temperature over twelve hours. Concentration and addition of dichloromethane (25mL) to the residue followed by washing the organic solution with 0.1N aqueous hydrochloric acid (2x 25mL) and drying over anhydrous magnesium sulfate gave the crude product. Filtration and concentration afforded **cis-1,5-cyclooctylene bis[4-((trans-4-tert-butoxycarbonylaminomethylcyclohexylene**

methylene)carbamoyl)-1-piperazinecarboxylate] (534mg, 56% yield) as a colorless solid.

5 ¹H NMR (CDCl₃): 4.80 (m, 2H), 4.70 (tr, 2H), 4.65 (tr, 2H),
3.45 (m, 8H), 3.35 (m, 8H), 3.10 (tr, 4H), 2.95 (tr, 4H),
1.95-1.50 (m, 24H), 1.45 (s, 18H), 1.00-0.90 (m, 8H).

10 *cis*-1,5-Cyclooctylene bis[4-((trans-4-aminomethylcyclohexylenemethylene)carbamoyl)-1-piperazinecarboxylate] (Compound 4):

15 *cis*-1,5-Cyclooctylene bis[4-((trans-4-tert-butoxycarbonylaminomethylcyclohexylenemethylene)carbamoyl)-1-piperazinecarboxylate] (534mg, 0.59mmol.) was treated with trifluoroacetic acid (5mL) and the mixture was concentrated in vacuo to a red oil after 15 minutes. The crude material was taken into water (10mL) and the aqueous suspension filtered through Millipore filter paper type GV (0.22μm) to give a yellow solution. Purification by preparative reverse phase HPLC and lyophilization gave *cis*-1,5-cyclooctylene bis[4-((trans-4-aminomethylcyclohexylenemethylene)carbamoyl)-1-piperazinecarboxylate (Compound 4) bis-hydrochloride as a nearly colorless solid.

20 ¹H-NMR (300MHz, DMSO-d₆): 8.00 (br s, 6H), 6.60 (m, 2H), 4.65 (m, 2H), 3.40 (s, 8H), 3.30 (s, 8H), 2.85 (m, 4H), 2.60 (tr, 4H), 1.80-1.30 (m, 24H), 0.90-0.70 (m, 8H).

25 Electrospray LRMS: Calculated for C₃₆H₆₄N₈O₆: MH⁺: 706.0; MH₂⁺²/2: 353.5
30 Found: MH⁺: 705.7; MH₂⁺²/2: 353.3

35 Proceeding in a fashion analogous to the procedure described in Example 4 and substituting different starting materials, the following compounds of the invention were prepared:

cis-1,5-cyclooctylene bis{4-[2-(4-amidinophenyl)ethyl carbamoyl]-1-piperazinecarboxylate} (Compound 33) ¹H-NMR (300MHz, DMSO-d₆): 9.3(s, 4H), 9.0(s, 4H), 7.7(d, 4H), 7.4(d,

4H), 6.7(t, 2H), 4.6(m, 2H), 3.8(m, 52H), 2.8(t, 4H), 1.7(m, 10H);
cis-1,5-cyclooctylene bis[4-(5-aminopentylcarbamoyl)-1-piperazinecarboxylate] (Compound 34); Electrospray LRMS:
5 Calculated for $C_{30}H_{56}N_8O_6$: MH^+ : 625.8; Found: MH^+ : 625.7;
cis-1,5-cyclooctylene bis[4-(6-aminohexylcarbamoyl)-1-piperazinecarboxylate] (Compound 35); Electrospray LRMS:
Calculated for $C_{32}H_{60}N_8O_6$: MH^+ : 653.9; Found: MH^+ : 654.2;
cis-1,5-cyclooctylene bis[4-(5-amino-2-pentenylcarbamoyl)-1-piperazinecarboxylate] (Compound 36); Electrospray LRMS:
10 Calculated for $C_{30}H_{52}N_8O_6$: MH^+ : 621.8; Found: MH^+ : 621.5;
cis-1,5-cyclooctylene bis[4-(4-aminobutylcarbamoyl)-1-piperazinecarboxylate] (Compound 37); Electrospray LRMS:
Calculated for $C_{28}H_{52}N_8O_6$: MH^+ : 597.8; Found: MH^+ : 596.9;
15 *cis*-1,5-cyclooctylene bis{4-[2-(2-aminoethoxy)ethylcarbamoyl]-1-piperazinecarboxylate} (Compound 38); Electrospray LRMS:
Calculated for $C_{28}H_{52}N_8O_8$: MH^+ : 628.8; Found: MH^+ : 628.5;
cis-1,5-cyclooctylene bis[4-(*trans*-4-aminomethylcyclohexylaminoformyloxy)-1-piperidinecarboxylate]
20 (Compound 39); Electrospray LRMS: Calculated for $C_{36}H_{62}N_6O_8$:
 MH^+ : 706.9; Found: MH^+ : 707.7;
cis-1,5-cyclooctylene bis[N-2-(*trans*-4-aminomethylcyclohexylaminoformyloxy)ethyl-N-methylaminocarboxylate] (Compound 40); Electrospray LRMS:
25 Calculated for $C_{32}H_{58}N_6O_8$: MH^+ : 654.9; Found: MH^+ : 655;
cis-1,5-cyclooctylene bis[N-2-(*trans*-4-aminomethylcyclohexylmethylaminoformyloxy)ethyl-N-methylaminocarboxylate] (Compound 41); Electrospray LRMS:
Calculated for $C_{34}H_{62}N_6O_8$: MH^+ : 683.9; Found: MH^+ : 683.5;
30 *trans*-1,4-cyclohexylenedimethylene bis[4-(*trans*-4-aminomethylcyclohexylmethylcarbamoyl)-1-piperazinecarboxylate] (Compound 42); Electrospray LRMS: Calculated for $C_{36}H_{64}N_8O_6$:
 MH^+ : 706; Found: MH^+ : 704.6; and
cis-1,5-cyclooctylene bis[4-(*trans*-4-aminomethylcyclohexylmethylaminoformyloxy)-1-piperidinecarboxylate] (Compound 43); Electrospray LRMS:
35 Calculated for $C_{38}H_{64}N_6O_8$: MH^+ : 736; Found: MH^+ : 735.6.

Example 5

cis-5-[4-(5-aminopentylcarbamoyl)piperazin-1-ylformyloxy]cyclooctyl

5 **4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate
(Compound 50)**

The following example describes the preparation of an unsymmetrical compound of this invention in which R² is 4-(4-aminobutylcarbamoyl)piperazin-1-ylformyloxy, R³ is 4-(4-aminobutylcarbamoyl)piperazin-1-ylformyloxy and Y is *cis*-1,5-cyclooctylene.

cis-1,5-Cyclooctylenediol bischloroformate (1.91 g, 7.1 mmol) was taken into dichloromethane (20 mL) and a solution of tert-butyl 1-piperazinecarboxylate (1.3g, 7.1 mmol) and diisopropylethylamine (1.3 mL, 7.1 mmol) in dichloroethane (10 mL) was added dropwise. The mixture was stirred 10 minutes at room temperature and then aqueous hydrochloric acid (0.1M, 30 mL) was added. The organic layer was separated, dried (anhydrous ammonium sulfate), filtered and concentrated.

20 Purification of the residue by silica gel flash chromatography eluting with ethyl ether/hexane (1:1) gave *cis*-5-chloroformyloxycyclooctyl 4-tert-buxtoxycarbonyl-1-piperazinecarboxylate (663.1 mg, 1.6 mmol) as a colorless oil.

25 tert-Butyl-4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate (383.7 mg, 1.1 mmol) was treated with neat trifluoroacetic acid (2 mL) at room temperature until a homogenous solution was obtained. The solution was concentrated in vacuo to a thick oil. The oil was taken into water (10 mL) and 5M aqueous sodium hydroxide was added dropwise until the solution was pH 7.5-8.0. *cis*-5-Chloroformyloxycyclooctyl 4-tert-buxtoxycarbonyl-1-piperazinecarboxylate(447.7 mg, 1.1 mmol) in THF (3 mL) was added to the solution with rapid stirring and while continuing 30 to add 5M sodium hydroxide to maintain pH 7.5-8.0. 5M Sodium hydroxide (10 mL) was added to adjust the solution to pH 14 and then ethyl ether (1 mL) was added. The mixture was allowed to stand for 15 minutes at room temperature giving a white solid.

The solid was collected by filtration and washed with ice water (1x), acetonitrile (1x) and ethyl ether (1x) and dried to give *cis*-5-(4-tert-butoxycarbonylpiperazin-1-ylformyloxy)cyclooctyl 4-guanidinobenzylcarbamoyl-1-piperazinecarboxylate (527.2 mg, 0.85 mmol) as a white solid.

5 *cis*-5-(4-tert-Butoxycarbonylpiperazin-1-ylformyloxy)cyclooctyl 4-guanidinobenzylcarbamoyl-1-piperazinecarboxylate (129 mg, 0.196 mmol) was treated with neat trifluoroacetic acid (1 mL) until a homogenous solution
10 was obtained. The solution was concentrated in vacuo to a colorless oil. The oil was taken into N,N-dimethylformamide (2 mL) and then diisopropylethylamine (340 μ L, 2 mmol) was added. 5-(tert-butoxycarbonyl)aminopentyl isocyanate (44 mg, 0.2 mmol) in N,N-dimethylformamide (500 μ L) was added to the
15 solution and the mixture was stirred 12 hours at room temperature. The mixture was concentrated in vacuo and the residue was combined with water (5 mL) and treated with trifluoroacetic acid (2 mL) until a homogenous solution was obtained. The solution was concentrated in vacuo and the
20 residue was taken into water (5 mL). Purification by preparative HPLC and subsequent lyophilization gave *cis*-5-[4-(5-aminopentylcarbamoyl)piperazin-1-ylformyloxy]cyclooctyl 4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate as a colorless oil.

25

Electrospray LRMS: Calculated for $C_{33}H_{54}N_{10}O_6$: MH^+ : 687.9; Found: MH^{+2} : 687.6.

30 Proceeding in a fashion analogous to the procedure described in Example 5 or by other methods described herein and substituting different starting materials the following compounds of the invention were prepared:
cis-5-[4-(4-aminobutylcarbamoyl)piperazin-1-ylformyloxy)cyclooctyl
35 4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate (Compound 51);

Electrospray LRMS: Calculated for $C_{32}H_{52}N_{10}O_6$: MH^+ : 673.8; Found: MH^+ : 673.8;

cis-5-[4-(4-*trans*-aminomethylcyclohexylmethylcarbamoyl) piperazin-1-ylformyloxy]cyclooctyl

4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate
(Compound 52);

5 **Electrospray LRMS:** Calculated for C₃₆H₅₇N₁₀O₆: MH⁺: 726.9;
Found: MH⁺: 727.3;

cis-5-[4-(3-aminopropylcarbamoyl)piperazin-1-ylformyloxy]cyclooctyl

4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate
10 (Compound 53);

Electrospray LRMS: Calculated for C₃₁H₅₀N₁₀O₆: MH⁺: 659.8;
Found: MH⁺: 659.2; and

cis-5-[4-(6-aminohexylcarbamoyl)piperazin-1-ylformyloxy]cyclooctyl

15 4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate
(Compound 54);

Electrospray LRMS: Calculated for C₃₄H₅₄N₉O₆: MH⁺: 686.9; Found:
MH⁺: 686.4.

20

Example 6

cis-1,5-Cyclooctylene bis(4-{4-[1,2,3-tri(1-acetoxyethoxycarbonyl)guanidino]benzylcarbamoyl}-1-piperazinecarboxylate)

25 The following example describes the preparation of a prodrug derivative of a compound of the invention in which Z is guanidino, X¹ is -X⁶-X⁷-X⁸-, wherein n₆ is 0, n₈ is 1 and X⁷ is 1,4-phenylene, X² is -NHC(O)-, X³ is 1,4-piperazinylene, X⁴ is -C(O)O-, Y is *cis*-1,5-cyclooctylene and R⁴ is 1-acetoxyethoxycarbonyl.

30 **cis**-1,5-Cyclooctylene bis[4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate] (49 mg, 0.065 mmol) was suspended in N,N-dimethylformamide (2 mL) and diisopropylethylamine (50 mL, 0.26 mmol) and acetoxyethyl para-nitrophenylcarbonate (70.4 mg, 0.26 mmol) was added sequentially. The mixture was stirred 1 hour at room temperature and then concentrated *in vacuo*. The residue was taken up into dichloromethane (25 mL) and the solution was

washed with saturated aqueous sodium dicarbonate (2x) and 0.1M aqueous hydrochloric acid (1x), dried (anhydrous magnesium sulfate), filtered and concentrated. The residue was purified by silica gel flash chromatography eluting with ethyl ether
5 following with ethyl acetate/ethanol (20:1). Concentrating gave *cis*-1,5-cyclooctylene bis(4-{4-[1,2,3-tri(1-acetoxyethoxycarbonyl)guanidino]benzylcarbamoyl}-1-piperazinecarboxylate] (40 mg, 0.031 mmol) as a colorless solid.

10

Electrospray LRMS: Calculated for $C_{56}H_{76}N_{12}O_{22}$: MH^+ : 1269:3; Found: MH^+ : 1269.4.

Proceeding in a fashion analogous to the procedure described in Example 6 or by other methods described herein and
15 substituting different starting materials the following prodrug derivatives of compounds of the invention were prepared: *cis*-5-[4-(5-N-acetylglycylaminopentylcarbamoyl)piperazin-1-ylformyloxy)cyclooctyl] 4-guanidinobenzylcarbamoyl-1-piperazinecarboxylate); **Electrospray LRMS:** Calculated for
20 $C_{37}H_{59}N_{11}O_8$: MH^+ : 786.9; Found: MH^+ : 786.5; and *cis*-1,5-cyclooctylene bis(4-{4-[1,2-di(1-acetoxyethoxycarbonyl)amidino]benzylcarbamoyl}-1-piperazinecarboxylate)); **Electrospray LRMS:** Calculated for
 $C_{64}H_{92}N_{12}O_{22}$: MH^+ : 1381.7; Found: MH^+ : 1403.

25

VI. In Vitro Tryptase Inhibition Assay

The compounds to be assayed (approximately 1 mg) were dissolved in 200 μ L dimethylsulfoxide (DMSO) and diluted 1:10 into buffer containing 50 millimolar (mM) Tris-HCl (pH 8.2),
30 100 mM sodium chloride, and 0.05% polyoxyethylenesorbitan monolaurate (Tween-20 $^\circ$, available from Sigma, St. Louis, MO). Seven additional threefold dilutions were made from the initial dilution into the same buffer supplemented with 10% DMSO. Aliquots (50 microliters, μ L) from each of the eight dilutions
35 in the series were transferred to individual wells in a 96-well U-bottom microtiter plate. 25 μ L of a stock solution of trypsin was added to each well and the samples were mixed and incubated for one hour at room temperature (trypsin was

purified from human lung and skin tissue preparations, HMC-1 (human mast cell line) and also obtained from commercial sources (ICN Biomedicals, Irvine, California; Athens Research & Technology, Athens, Georgia)). Each inhibitor had similar affinity to tryptase from all of these sources. The tryptase solution was prepared by placing 60 μ g/mL of tryptase into solution with 10 mM MES (2-[N-Morpholino]ethane sulfonic acid) containing 2 mM CaCl₂, 20% glycerol and 50 μ g/mL heparin. The enzyme reaction was initiated with the addition of the synthetic tripeptide substrate, tosyl-Gly-Pro-Lys-p-nitroanilide (available from Sigma, 25 μ L; 0.5 mM final concentration). The microtiter plates were immediately transferred to a UV/MAX Kinetic Microplate Reader (Molecular Devices) and hydrolysis of the chromogenic substrate was followed spectrophotometrically at 405 nanometers (nM) for five minutes. The enzyme assays routinely yielded linear progress curves under these conditions. Initial velocity measurements calculated from the progress curves by a kinetic analysis program (BatchKi; Petr Kuzmic, University of Wisconsin, Madison, WI) were used to determine apparent inhibition constants for compounds 1, 2 and 4.

A potent tryptase inhibitor of the present invention, Compound 3, is classified as a tight binding inhibitor because its apparent affinity for tryptase (K_i') is calculated to be 200 pM using the program BatchKi) is comparable to the enzyme concentration used in the assay. However, K_i' varies with the enzyme concentration used in the enzyme assay. A graphical method (Henderson, P.J.F., Biochem. J. 127, 321 (1972)) was used to determine the K_i' of Compound 3 that is independent of the tryptase concentration. In this experiment, the concentrations of tryptase (0.25, 0.50, 1.0 and 2.0 nM) and Compound 3 (40, 110, 340 and 680 pM) were varied in pre-incubation mixtures for 1 hour before adding substrate (500 μ M tosyl-gly-pro-lys-para-nitroanilide). The IC₅₀ of Compound 3 was determined at each concentration of tryptase. The y-intercept of a replot of IC₅₀ (ordinate) versus tryptase concentration (abscissa) produces a value for K_i' . The true dissociation constant of a competitive inhibitor, K_i , is

calculated from the relationship (See, Morrison, J.F., Methods in Enzymology 63, 437-467 (1969)):

$$K_i = K_i' / (1 + S/K_m), \text{ where } S = 500 \mu\text{M} \text{ and } K_m = 300 \mu\text{M}$$

5

The dissociation constant of Compound 3 from tryptase is calculated to be 60 pM by this method.

The inhibition constants (K_i' , micromolar (μM)) were determined for the compounds of the present invention.

10 According to the present invention, a compound was termed "active" or "effective" as a tryptase inhibitor when its K_i' was less than 5 μM .

Proceeding as in the above *in vitro* assay compounds of the invention were tested and the following K_i (μM) values 15 were obtained: Compound 1 (0.004), Compound 2 (0.002), Compound 3 (0.0002), Compound 4 (0.0158), Compound 5 (0.002), Compound 6 (0.00037), Compound 7 (0.005), Compound 8 (0.03), Compound 9 (0.493), Compound 10 (0.00047), Compound 11 (0.207), Compound 12 (0.26), Compound 13 (0.00013), Compound 14 (1.3), 20 Compound 15 (0.302), Compound 16 (0.0015), Compound 17 (0.0049), Compound 18 (0.713), Compound 19 (1.51), Compound 20 (0.00081), Compound 21 (0.0609), Compound 22 (0.009), Compound 23 (0.119), Compound 24 (0.00016), Compound 25 (0.734), Compound 26 (0.332), Compound 27 (0.614), Compound 28 (0.0087), 25 Compound 29 (0.0038), Compound 30 (0.008), Compound 31 (0.0266), Compound 32 (0.0122), Compound 33 (0.44), Compound 34 (0.011), Compound 35 (1.44), Compound 36 (0.125), Compound 37 (0.508), Compound 38 (0.75), Compound 39 (0.858), Compound 40 (1.39), Compound 41 (1.1), Compound 42 (0.064), Compound 43 (1.45), Compound 44 (0.008), Compound 45 (0.114), Compound 46 (0.772), Compound 47 (0.00042), Compound 48 (2.3), Compound 49 (0.0034), Compound 50 (0.00045), Compound 51 (0.0038), Compound 52 (0.00048), Compound 53 (0.044) and Compound 54 (0.02).

35 **VII. In Vivo Testing**

The allergic sheep model of asthma was employed for the *in vivo* evaluation of the compounds of the invention as antiasthmatics. These methods have been published previously

(see Abraham et al. (1983) *Am. Rev. Respir. Dis.* 128:839-844; Allegra et al. (1983) *J. Appl. Physiol.* 55:726-730; Russi et al. (1985) *J. Appl. Physiol.* 59:1416-1422; Soler et al. (1989) *J. Appl. Physiol.* 67:406-413. Each sheep serves as its own control. Body weights for these animals ranged from 20-50 kilograms.

In these studies, 50 µg of Compound 3 of the invention was dissolved in buffered saline and the total solution delivered as an aerosol 0.5 hours before, 4 hours 10 after, and 24 hours after antigen challenge (total dose = 150 µg; n = 3). This compound produced a significant attenuation of the early and late responses to the antigen challenge as measured by Specific Lung Resistance (SRL). This is shown in Figure 1. Similar results were achieved for Compound 2 as 15 shown in Figure 5. The peak early response was taken as the average of the maximum values occurring immediately post-challenge. Peak late responses were calculated by averaging the maximum response values obtained for each animal within the 6-8 hour time period. This approach is conservative 20 and eliminates the possible reduction in the late response due simply to averaging.

Twenty-four hours after antigen challenge in both the control and drug trial, the sheep developed airway hyperresponsiveness. Airway hyperresponsiveness is expressed 25 as PC400, the concentration of carbachol that causes a 400% increase in SRL; therefore, a decrease in PC400 indicates hyperresponsiveness. Compound 3 was found to block the onset of hyperresponsiveness. As shown in Figure 2, this compound maintained the PC400 at substantially the baseline value of 32 breath units. The number of breath units fell to 12 for those 30 animals in the control group. Thus, treatment with Compound 3 of the invention resulted in a significant improvement in airway function in antigen challenged sheep. Likewise, Compound 2 also shows similar results, as shown in Figure 6.

Compound 3 was also found to possess oral activity. Three doses of the compound (2 mg in 10 mL water) were administered to sheep through an intergastric tube 1 hr before challenge, 4 hours post-challenge, and 24 hours post-challenge.

As illustrated in Figure 5, animals treated with this compound had an early phase SRL of about 175. Untreated animals showed an SRL of about 250. With respect to late phase reaction, animals treated with this compound showed an SRL of about 50 as compared to an SRL of over 200 for untreated animals. Thus, this compound showed significant anti-asthmatic properties when delivered orally.

Aerosol treatment with Compound 3 prior to antigen challenge was also found to be effective in attenuating the early and late responses to the antigen challenge as measured by Specific Lung Resistance (SRL). For these studies, the animals were predosed, by aerosol administration, with Compound 3 (0.5 mg/day X 3 days, with an additional 0.5 mg one half hour before antigen challenge). Figure 7 shows a significant attenuation of early and late phase response to antigen challenge resulting from pretreatment with Compound 3. Figure 8, likewise shows a significant improvement in airway function.

Thus, the present invention provides compounds and compositions that are useful for the prevention and treatment of immunomediated inflammatory disorders, particularly those associated with the respiratory tract, including asthma, and the hyperresponsiveness phase associated with chronic asthma, in addition to allergic rhinitis. The present invention is also recognized as providing a method for treating immunomediated inflammatory disorders that are susceptible to treatment with a compound of the present invention.

The disclosures in this application of all articles and references, including patents and patent applications, are incorporated herein by reference.

It is to be understood that the above description is intended to be illustrative and not restrictive. Many embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.

WHAT IS CLAIMED IS:

1 decahydronaphthylene, *trans*-decahydronaphthylene,
2 perhydrophenanthrene, bicyclo[2.2.1]heptylene,
3 bicyclo[2.2.2]octylene, dioxabicyclo[3.3.0]octylene or
4 tetracyclo[3.3.1.1^{3,7}]decylene.

1 4. The compound of Claim 3 in which X³ is 1,4-
2 piperazinylene, 1,4-piperidylene, 1,4-perhydro-7H-1,4-
3 diazepinylene or -X⁹-X¹⁰- (wherein X⁹ is methylene and X¹⁰ is
4 1,4-piperidylene) and X⁴ is -C(O)- or -C(O)O-; or X³ is
5 (C₁₋₄)alkyne and X⁴ is -N(R¹)C(O)O- (wherein R¹ is hydrogen or
6 methyl).

1 5. The compound of Claim 4 in which n₈ and n₅ are
2 independently 0 or 1.

1 6. The compound of Claim 5 in which n₅ is 0 and Y
2 is cyclooctylene.

1 7. The compound of Claim 6 in which Z is guanidino,
2 X¹ is -X⁶-X⁷-X⁸- (wherein n₆ is 0, n₈ is 1 and X⁷ is 1,4-
3 phenylene), X² is -NHC(O)-, X³ is 1,4-piperazinylene, X⁴ is -
4 C(O)O- and Y is *cis*-1,5-cyclooctylene, namely *cis*-1,5-
5 cyclooctylene bis[4-(4-guanidinobenzylcarbamoyl)-1-
6 piperazinecarboxylate] and the pharmaceutically acceptable
7 salts thereof.

1 8. The compound of Claim 6 in which Z is amino, X¹
2 is -X⁶-X⁷-X⁸- (wherein n₆ is 1, n₈ is 1 and X⁷ is *trans*-1,4-
3 cyclohexylene), X² is -NHC(O)-, X³ is 1,4-piperazinylene, X⁴ is
4 -C(O)O- and Y is *cis*-1,5-cyclooctylene, namely *cis*-1,5-
5 cyclooctylene bis[4-(*trans*-4-aminomethylcyclohexylmethyl-
6 carbamoyl)-1-piperazinecarboxylate] and the pharmaceutically
7 acceptable salts thereof.

1 9. The compound of Claim 6 in which Z is guanidino,
2 X¹ is -X⁶-X⁷-X⁸- (wherein n₆ is 0, n₈ is 1 and X⁷ is 1,4-
3 phenylene), X² is -NHC(O)-, X³ is methylene, X⁴ is -NHC(O)O-
4 and Y is *cis*-1,5-cyclooctylene, namely *cis*-1,5-cyclooctylene

1 bis[4-guanidinobenzylcarbamoylmethylaminocarboxylate) and the
2 pharmaceutically acceptable salts thereof.

1 10. The compound of Claim 6 in which Z is guanidino,
2 X¹ is -X⁶-X⁷-X⁸- (wherein n₆ is 0, n₈ is 1 and X⁷ is 1,4-
3 phenylene), X² is -C(O)O-, X³ is 1,4-piperazinylene, X⁴ is
4 -C(O)O- and Y is *cis*-cyclooctylene, namely *cis*-1,5-
5 cyclooctylene bis[4-(4-guanidinophenylacetyl)-1-piperazine
6 carboxylate] and the pharmaceutically acceptable salts thereof.

1 11. The compound of Claim 6 which is selected from
2 the group consisting of:

3 *cis*-1,5-cyclooctylene bis{4-[4-(2-aminoethyl)benzylcarbamoyl]-
4 1-piperazinecarboxylate};
5 *cis*-1,5-cyclooctylene bis[4-(5-aminopentylcarbamoyl)-1-
6 piperazinecarboxylate];
7 *cis*-1,5-cyclooctylene bis{4-[4-(aminomethyl)piperid-1-
8 ylcarbonylamino]butylaminocarboxylate};
9 *cis*-1,5-cyclooctylene bis[4-(6-aminohexylcarbamoyl)-1-
10 piperazinecarboxylate];
11 *cis*-1,5-cyclooctylene bis{4-[4-(aminomethyl)piperid-1-
12 ylcarbonylaminoethyl)-1-piperidinecarboxylate};
13 *cis*-1,5-cyclooctylene bis[4-(*trans*-4-
14 aminomethylcyclohexylmethyldcarbamoyl)-1-(perhydro-7H-1,4-
15 diazepine)carboxylate];
16 *cis*-1,5-cyclooctylene[4-(4-aminomethylbicyclo[2.2.2]oct-1-
17 ylmethylcarbamoyl)-1-piperazinecarboxylate];
18 *cis*-1,5-cyclooctylene bis[4-(5-amino-2-pentenylcarbamoyl)-1-
19 piperazinecarboxylate];
20 *cis*-1,5-cyclooctylene bis[4-(4-aminobutylcarbamoyl)-1-
21 piperazinecarboxylate];
22 *cis*-1,5-cyclooctylene bis{4-[2-(2-aminoethoxy) ethylcarbamoyl]-
23 1-piperazinecarboxylate};
24 *cis*-1,5-cyclooctylene bis[4-(*trans*-4-aminomethylcyclohexyl
25 aminoformyloxy)-1-piperazinecarboxylate];
26 *cis*-1,5-cyclooctylene bis{N-2-(*Trans*-4-aminomethylcyclohexyl
27 aminoformyloxy)ethyl-N-methylaminocarboxylate};

1 *cis*-1,5-cyclooctylene bis[4-(4-aminomethylbenzylcarbamoyl)-1-
2 piperazinecarboxylate];
3 *cis*-1,5-cyclooctylene bis{N-2-(*trans*-4-
4 aminomethylcyclohexylmethylaminoformyloxy)ethyl-N-
5 methylaminocarboxylate};
6 *cis*-1,5-cyclooctylene bis[4-(*trans*-4-
7 aminomethylcyclohexylmethylaminoformyloxy)-1-
8 piperidinecarboxylate];
9 *cis*-1,5-cyclooctylene bis{4-[3-(4-guanidinophenyl)propionyl]-1-
10 piperazinecarboxylate};
11 *cis*-1,5-cyclooctylene bis{4-[2-(1-amidinopiperid-4-
12 yl)ethylcarbamoyl]-1-piperazinecarboxylate};
13 *cis*-1,5-cyclooctylene bis[4-(*trans*-4-aminomethylcyclohexyl
14 carbonyl)-1-piperidinecarboxylate];
15 *cis*-1,5-cyclooctylene bis{4-[4-(2-aminoethyl)phenylacetyl]-1-
16 piperazinecarboxylate};
17 *cis*-1,5-cyclooctylene bis{4-[4-(2-aminoethyl)benzoyl[-1-
18 piperazinecarboxylate};
19 *cis*-1,5-cyclooctylene bis{4-[4-(1-aminoprop-2-yl)benzoyl]-1-
20 piperazinecarboxylate};
21 *cis*-1,5-cyclooctylene bis{4-[3-(1-amidinopiperid-4-
22 yl)propionoyl]-1-piperazinecarboxylate};
23 *cis*-1,5-cyclooctylene bis{4-[3-(4-guanidinophenyl)propionoyl]-1-
24 piperazinecarboxylate};
25 *cis*-1,5-cyclooctylene bis{4-[4-(2-aminoethyl)piperid-1-yl]-1-
26 piperazinecarboxylate};
27 *cis*-1,5-cyclooctylene bis{4-[*trans*-4-(2-
28 aminoethyl)cyclohexylcarbonyl]-1-piperazinecarboxylate};
29 *cis*-1,5-cyclooctylene bis{4-[*trans*-4-(2-
30 aminoethyl)cyclohexylacetyl]-1-piperazinecarboxylate};
31 *cis*-1,5-cyclooctylene bis{4-[2-(4-
32 amidinophenyl)ethylcarbamoyl]-1-piperazinecarboxylate};
33 *cis*-1,5-cyclooctylene bis[4-(1-amidinopiperid-4-ylacetyl)-1-
34 piperazinecarboxylate];
35 *cis*-1,5-cyclooctylene bis{4-(1-amidinopiperid-4-
36 ylmethylcarbamoyl)-1-piperazinecarboxylate};
37 *cis*-1,5-cyclooctylene bis[4-(4-amidinophenylacetyl)-1-
38 piperazinecarboxylate);

1 *cis*-1,5-cyclooctylene bis[4-(4-amidinobenzylcarbamoyl)-1-
2 piperazinecarboxylate]; *cis*-1,5- cyclooctylene bis[4-(4-
3 amidinobenzoylaminomethyl)-1-piperidinecarboxylate; *cis*-1,5-
4 cyclooctylene bis[4-(4-amidinopiperid-1-ylcarbonylaminomethyl)-
5 1-piperidinecarboxylate; *cis*-1,5-cyclooctylene bis[4-(4-
6 guanidinophenylcarbonylaminomethyl)-1-piperadinecarboxylate];
7 and the pharmaceutically acceptable salts thereof.

1 12. The compound of Claim 5 in which n5 is 1 and Y
2 is cyclohexylene.

1 13. The compound of Claim 12 in which Z is
2 guanidino, X¹ is -X⁶-X⁷-X⁸- (wherein n6 is 0, n8 is 1 and X⁷ is
3 1,4-phenylene) X² is -NHC(O)-, X³ is methylene, X⁴ is -NHC(O)O-
4 and Y is *trans*-1,4-cyclohexylenedimethylene, namely *trans*-1,4-
5 cyclohexylenedimethylene bis(4-guanidinobenzylcarbamoyl
6 methylaminocarboxylate) and the pharmaceutically acceptable
7 salts thereof.

1 14. The compound of Claim 12 which is selected from
2 the group consisting of:
3 *trans*-1,4-cyclohexylenedimethylene bis[4-(*trans*-4-
4 aminomethylcyclohexylmethylcarbamoyl)-1-piperazinecarboxylate];
5 *trans*-1,4-cyclohexylenedimethylene bis[4-(4-
6 (aminomethyl)piperid-1-ylcarbonylaminomethyl)-1-
7 piperidinecarboxylate]; *cis*-1,4-cyclohexylenedimethylene bis[4-
8 (4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate]; and the
9 pharmaceutically acceptable salts thereof.

1 15. The compound of Claim 5 in which n5 is 0 and Y
2 is cyclohexylene.

1 16. The compound of Claim 15 which is selected from
2 the group consisting of:
3 *trans*-1,4-cyclohexylene bis[4(4-guanidinobenzylcarbamoyl)-1-
4 piperazinecarboxaldehyde];
5 *trans*-1,4-cyclohexylene bis[4(4-2-aminoethylbenzoyl-1-
6 piperazinecarboxaldehyde]; 1,2-cyclohexylene bis[4-(4-

1 guanidinobenzylcarbamoyl)-1-piperazinecarboxaldehyde]; and the
2 pharmaceutically acceptable salts thereof.

1 17. The compound of Claim 5 in which n5 is 0 and Y
2 is 4,8-dioxabicyclo[3.3.0]octylene.

1 18. The compound of Claim 17 in which Z is
2 guanidino, X¹ is -X⁶-X⁷-X⁸- (wherein n6 is 0, n8 is 1 and X⁷ is
3 1,4-phenylene), X² is -NHC(O)-, X³ is 1,4-piperazinylene, X⁴ is
4 -C(O)O- and Y is trans-2,6-(4,8-dioxabicyclo[3.3.0]octylene),
5 namely trans-2,6-(4,8-dioxabicyclo[3.3.0]octylene) bis[4-(4-
6 guanidinobenzylcarbamoyl)-1-piperazinecarboxylate] and the
7 pharmaceutically acceptable salts thereof.

1 19. The compound of Claim 5 in which n5 is 1 and Y
2 is bicyclo[2.2.2]oct-5-enylene.

1 20. The compound of Claim 19 in which Z is
2 guanidino, X¹ is X⁶-X⁷-X⁸- (wherein n6 is 0, n8 is 1 and X⁷ is
3 1,4-phenylene), X² is -NHC(O)-, X³ is 1,4-piperazinylene, X⁴ is
4 -C(O)O- and Y is trans-2,3-bicyclo[2.2.2]oct-5-
5 enylenedimethylene, namely trans-2,3-bicyclo[2.2.2]oct-5-
6 enylenedimethylene bis[4-(4-guanidinobenzylcarbamoyl)-1-
7 piperazinecarboxylate] and the pharmaceutically acceptable
8 salts thereof.

1 21. The compound of Claim 5 in which n5 is 1 and Y
2 is tetracyclo[3.3.1.1^{3,7}]decylene.

1 22. The compound of Claim 21 wherein the compound is
2 selected from the group consisting of:
3 cis-1,5-tetracyclo[3.3.1.1^{3,7}]decylenedimethylene bis[4-(4-
4 guanidinobenzylcarbamoyl)-1-piperazinecarboxylate];
5 cis-1,5-tetracyclo[3.3.1.1^{3,7}]decylenedimethylene bis[4-(4-
6 guanidinobenzylcarbamoyl)-1-piperazinecarboxaldehyde]; and the
7 pharmaceutically acceptable salts thereof.

1 23. The compound of Claim 5 in which n5 is 1 and Y
2 is bicyclo[2.2.2]octylene.

1 24. The compound of Claim 23 in which Z is
2 guanidino, X¹ is -X⁶X⁷X⁸- (wherein n6 is 0, n8 is 1 and X⁷ is
3 1,4-phenylene), X² is -NHC(O)-, X³ is 1,4-piperazinylene, X⁴ is
4 -C(O)O- and Y is 1,4-bicyclo[2.2.2]octylenedimethylene, namely
5 1,4-bicyclo[2.2.2]octylenedimethylene bis[4-(4-
6 guanidinobenzylcarbamoyl)-1-piperazinecarboxylate] and the
7 pharmaceutically acceptable salts thereof.

1 25. A compound of the formula:

2 R²-Y-R³

3 in which R² and R³ are independently Z-X¹-X²-X³-X⁴-X⁵-
4 in which:
5 Z is amino, guanidino or amidino;
6 Y is optionally substituted cyclo(C₃₋₁₄)alkylene or optionally
7 substituted heterocyclo(C₃₋₁₄)alkylene;
8 X¹ is optionally substituted (C₃₋₆)alkylene, optionally
9 substituted oxa(C₄₋₆)alkylene or -X⁶-X⁷-X⁸- (wherein X⁷ is
10 optionally substituted phenylene, optionally substituted
11 cyclo(C₃₋₆)alkylene or optionally substituted heterocyclo(C₃₋₆)
12 alkylene and X⁶ and X⁸ are optionally substituted
13 (C_{n6})alkylene and optionally substituted (C_{n8})alkylene,
14 respectively, wherein the sum of n6 and n8 is equal to 1, 2, 3
15 or 4, with the proviso that when Z is amino n6 is not 0);
16 X² and X⁴ are independently -C(O)-, -C(O)O-, -OC(O)-,
17 -C(O)N(R¹)-, -N(R¹)C(O)-, -OC(O)N(R¹)-, -N(R¹)C(O)O-,
18 -N(R¹)C(O)N(R¹)- or -OC(O)O- (wherein each R¹ is independently
19 hydrogen, optionally substituted (C₁₋₈)alkyl or optionally
20 substituted cyclo(C₃₋₈)alkyl;
21 X³ is optionally substituted (C₁₋₈)alkylene, -X⁹-X¹⁰- or -X¹⁰-X⁹-
22 (wherein X⁹ is optionally substituted (C_{n9})alkylene, wherein n9
23 is 0, 1 or 2, and X¹⁰ is optionally substituted cyclo(C₃₋₈)
24 alkylene or optionally substituted heterocyclo(C₃₋₈)alkylene,
25 with the proviso that covalent bonds do not occur between
26 hetero atoms contained within X¹⁰ and hetero atoms contained
27 within either X² or X⁴); and

1 X^5 is optionally substituted (C_{n5})alkylene wherein $n5$ is 0, 1
2 or 2; with the proviso that R^2 and R^3 are not identical; and
3 the pharmaceutically acceptable salts and prodrugs thereof.

1 26. The compound of Claim 25 in which X^2 is
2 -C(O)NH-, -NHC(O)- or -NHC(O)O- and X^4 is -C(O)- or -C(O)O-.

1 27. The compound of Claim 26 in which Y is
2 cyclooctylene, cyclohexylene, cyclopentylene,
3 cis-decahydronaphthylene, trans-decahydronaphthylene,
4 perhydrophenanthrene, bicyclo[2.2.1]heptylene,
5 bicyclo[2.2.2]octylene, dioxabicyclo[3.3.0]octylene or
6 tetracyclo[3.3.1.1^{3,7}]decylene.

1 28. The compound of Claim 27 in which X^3 is 1,4-
2 piperazinylene, 1,4-piperidylene, 1,4-perhydro-7H-1,4-
3 diazepinylene or - X^9 - X^{10} - (wherein X^9 is methylene and X^{10} is
4 1,4-piperidylene) and X^4 is -C(O)- or -C(O)O-; or X^3 is
5 (C_{1-4})alkyne and X^4 is -N(R^1)C(O)O- (wherein R^1 is hydrogen or
6 methyl).

1 29. The compound of Claim 28 in which $n8$ and $n5$ are
2 independently 0 or 1.

1 30. The compound of Claim 29 in which $n5$ is 0 and Y
2 is cyclooctylene.

1 31. The compound of Claim 30 in which
2 R^2 is 4-(4-guanidinobenzylcarbamoyl)piperazin-1-ylformyloxy, R^3
3 is 4-(4-trans-aminomethylcyclohexylmethylcarbamoyl)piperazin-1-
4 ylformyloxy and Y is cis-1,5-cyclooctylene, namely
5 cis-5-[4-(4-trans-aminomethylcyclohexylmethylcarbamoyl)
6 piperazin-1-ylformyloxy]cyclooctyl 4-(4-
7 guanidinobenzylcarbamoyl)-1-piperazinecarboxylate and the
8 pharmaceutically acceptable salts thereof.

1 32. The compound of Claim 31 which is selected from
2 the group consisting of:

1 *cis*-5-[4-(5-aminopentylcarbamoyl)piperazin-1-
2 ylformyloxy]cyclooctyl
3 4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate;
4 *cis*-5-[4-(4-aminobutylcarbamoyl)piperazin-1-
5 ylformyloxy]cyclooctyl
6 4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate;
7 *cis*-5-[4-(3-aminopropylcarbamoyl)piperazin-1-
8 ylformyloxy]cyclooctyl
9 4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate; and
10 *cis*-5-[4-(6-aminohexylcarbamoyl)piperazin-1-
11 ylformyloxy]cyclooctyl
12 4-(4-guanidinobenzylcarbamoyl)-1-piperazinecarboxylate; and the
13 pharmaceutically acceptable salts thereof.

1 33. An aerosol composition for the treatment of
2 immunomediated inflammatory disorders comprising the compound
3 of claim 1 in an aerosolized pharmaceutically acceptable
4 carrier solution or dry powder.

1 34. The aerosol composition of Claim 33, wherein the
2 compound is selected from the group consisting of:
3 *trans*-1,4-cyclohexylenedimethylene bis(4-
4 guanidinobenzylcarbamoylmethylaminocarboxylate);
5 *cis*-1,5-cyclooctylene bis(4-
6 guanidinobenzylcarbamoylmethylaminocarboxylate);
7 *cis*-1,5-cyclooctylene bis[4-(4-guanidinobenzylcarbamoyl)-1-
8 piperazinecarboxylate];
9 *cis*-1,5-cyclooctylene bis[4-(*trans*-4-
10 aminomethylcyclohexylmethylcarbamoyl)-1-piperazinecarboxylate];
11 and
12 *cis*-1,5-cyclooctylene bis[4-(4-guanidinophenylacetyl)-1-
13 piperazinecarboxylate].

1 35. The aerosol composition of claim 33, wherein the
2 inflammatory disorder is asthma.

1 36. The aerosol composition of claim 33, wherein the
2 inflammatory disorder is allergic rhinitis.

1 37. The aerosol composition of claim 33 wherein said
2 compound is present in the pharmaceutically acceptable carrier
3 solution at a concentration between about 0.01 and 30 mg/ml.

1 38. The aerosol composition of claim 33 further
2 comprising a β -adrenergic agonist compound.

1 39. A pharmaceutical composition comprising the
2 compound of claim 1 in combination with a pharmaceutically
3 acceptable carrier.

1 40. The pharmaceutical composition of Claim 39,
2 wherein the compound is selected from the group consisting of:
3 *trans*-1,4-cyclohexylenedimethylene bis(4-
4 guanidinobenzylcarbamoylmethylaminocarboxylate);
5 *cis*-1,5-cyclooctylene bis(4-
6 guanidinobenzylcarbamoylmethylaminocarboxylate);
7 *cis*-1,5-cyclooctylene bis[4-(4-guanidinobenzylcarbamoyl)-1-
8 piperazinecarboxylate];
9 *cis*-1,5-cyclooctylene bis[4-*trans*-4-
0 aminomethylcyclohexylmethylcarbamoyl)-1-piperazinecarboxylate];
.1 and
2 *cis*-1,5-cyclooctylene bis[4-(4-guanidinophenylacetyl)-1-
3 piperazinecarboxylate].

1 41. The composition of claim 39 wherein said
2 pharmaceutical composition comprises a pharmaceutically
3 acceptable topical carrier.

1 42. An aerosol device, comprising the compound of
2 claim 1 in a pharmaceutically acceptable carrier solution or
3 dry powder, and a means for converting said solution or dry
4 powder into an aerosol form suitable for inhalation.

1 43. The aerosol device of Claim 42, wherein the
2 compound is selected from the group consisting of:
3 *trans*-1,4-cyclohexylenedimethylene bis(4-
4 guanidinobenzylcarbamoylmethylaminocarboxylate);

1 *cis*-1,5-cyclooctylene bis(4-
2 guanidinobenzylcarbamoylmethylaminocarboxylate);
3 *cis*-1,5-cyclooctylene bis[4-(4-guanidinobenzylcarbamoyl)-1-
4 piperazinecarboxylate];
5 [*cis*-1,5-cyclooctylene bis[4-(*trans*-4-
6 aminomethylcyclohexylmethylcarbamoyl)-1-piperazinecarboxylate];
7 and
8 *cis*-1,5-cyclooctylene bis[4-(4-guanidinophenylacetyl)-1-
9 piperazinecarboxylate].

1 44. The aerosol device of claim 42 further
2 comprising a β -adrenergic agonist compound.

1 45. The aerosol device of claim 44 wherein said β -
2 adrenergic agonist compound is selected from the group
3 consisting of albuterol, terbutaline, formoterol, fenoterol and
4 prenoline.

1 46. A method for treating an immunomediated
2 inflammatory disorder of the respiratory tract of a mammal,
3 said method comprising administering to said mammal an inhalant
4 composition comprising the compound of claim 1 in an
5 aerosolized pharmaceutically acceptable carrier solution or dry
6 powder.

1 47. The method of Claim 46, wherein the compound is
2 selected from the group consisting of:
3 *trans*-1,4-cyclohexylenedimethylene bis(4-
4 guanidinobenzylcarbamoylmethylaminocarboxylate);
5 *cis*-1,5-cyclooctylene bis(4-
6 guanidinobenzylcarbamoylmethylaminocarboxylate);
7 *cis*-1,5-cyclooctylene bis[4-(4-guanidinobenzylcarbamoyl)-1-
8 piperazinecarboxylate;
9 *cis*-1,5-cyclooctylene bis[4-(*trans*-4-
10 aminomethylcyclohexylmethylcarbamoyl)-1-piperazinecarboxylate];
11 and
12 *cis*-1,5-cyclooctylene bis[4-(4-guanidinophenylacetyl)-1-
13 piperazinecarboxylate].

1 48. The method of claim 47 further comprising a β -
2 adrenergic agonist compound.

1 49. The method of claim 48 wherein said β -adrenergic
2 agonist compound is selected from the group consisting of
3 albuterol, terbutaline, formoterol, fenoterol and prenalone.

1 50. A method for treating immunomediated
2 inflammatory skin conditions in a mammal, said method
3 comprising administering topically to said mammal a topical
4 composition comprising a therapeutically effective amount of
5 the compound of claim 1 in a pharmaceutically acceptable
6 topical carrier.

1 51. An oral composition for the treatment of
2 immunomediated inflammatory disorders comprising the compound
3 of claim 1 in a pharmaceutically acceptable carrier.

1 52. The oral composition of Claim 51, wherein the
2 compound is selected from the group of:
3 *trans*-1,4-cyclohexylenedimethylene bis(4-
4 guanidinobenzylcarbamoylmethylaminocarboxylate);
5 *cis*-1,5-cyclooctylene bis(4-
6 guanidinobenzylcarbamoylmethylaminocarboxylate);
7 *cis*-1,5-cyclooctylene bis[4-(4-guanidinobenzylcarbamoyl)-1-
8 piperazinecarboxylate];
9 *cis*-1,5-cyclooctylene bis[4-(*trans*-4-
10 aminomethylcyclohexylmethylicarbamoyl)-1-piperazinecarboxylate];
11 and
12 *cis*-1,5-cyclooctylene bis[4-(4-guanidinophenylacetyl)-1-
13 piperazinecarboxylate].

1 53. The composition of Claim 52 wherein the compound
2 is *cis*-1,5-cyclooctylene bis[4-(4-guanidinobenzylcarbamoyl)-1-
3 piperazinecarboxylate].

1 54. A method of treating rheumatoid arthritis in a
2 mammal, comprising administering to said mammal a

1 therapeutically effective amount of a compound of claim 1 to
2 thereby relieve said rheumatoid arthritis.

1 55. A method of treating conjunctivitis in a mammal,
2 said method comprising administering to said mammal a
3 therapeutically effective amount of the compound of claim 1 to
4 thereby relieve said conjunctivitis.

1 56. A method of treating syncytial virus infections
2 in a mammal said method comprising administering to said mammal
3 a therapeutically effective amount of the compound of claim 1.

1 57. The method of Claim 56, wherein the compound is
2 selected from the group of:
3 *trans*-1,4-cyclohexylenedimethylene bis(4-
4 guanidinobenzylcarbamoylmethylaminocarboxylate);
5 *cis*-1,5-cyclooctylene bis[4-
6 guanidinobenzylcarbamoylmethylaminocarboxylate);
7 *cis*-1,5-cyclooctylene bis[4-(4-guanidinobenzylcarbamoyl)-1-
8 piperazinecarboxylate];
9 *cis*-1,5-cyclooctylene bis[4-(*trans*-4-
10 aminomethylcyclohexylmethylecarbamoyl)-1-piperazinecarboxylate;
11 and
12 *cis*-1,5-cyclooctylene bis[4-(4-guanidinophenylacetyl)-1-
13 piperazinecarboxylate].




Figure 1




Figure 2




Figure 3

Compound 3 (2 mg x 3 oral; n = 2)




Figure 4

Compound 2 (0.1 mg x 3; n = 2)




Figure 5

Compound 2 (0.1 mg x 3; n = 2)






Figure 6

Compound 3 Pre-dosing (n = 3)**Figure 7**

Compound 3 Pre-dosing (*n* = 3)

(0.5 mg b.i.d. x 3 days + 0.5 mg 0.5 h before Ag)

Figure 8

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 95/11814

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 6	C07D295/32	C07D295/205	C07D211/58	C07D211/46	C07D211/34
	C07D211/26	C07D243/08	C07D493/04	C07C279/18	C07C271/24
	C07C271/20	A61K31/325	A61K31/155	A61K31/445	A61K31/495

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP-A-0 214 429 (KOWA CO. LTD.) 18 March 1987 see the whole document ---	1-45, 51-53
A	WO-A-94 20527 (ARRIS PHARMACEUTICAL CORPORATION) 15 September 1994 see the whole document ---	1-45, 51-53
E	WO-A-95 32945 (ARRIS PHARMACEUTICAL CORPORATION) 7 December 1995 see the whole document -----	1-45, 51-53

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *'A' document defining the general state of the art which is not considered to be of particular relevance
- *'B' earlier document but published on or after the international filing date
- *'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *'O' document referring to an oral disclosure, use, exhibition or other means
- *'P' document published prior to the international filing date but later than the priority date claimed

- *'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *'Z' document member of the same patent family

Date of the actual completion of the international search

26 January 1996

Date of mailing of the international search report

16.02.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patenttaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Hartrampf, G

INTERNATIONAL SEARCH REPORT

Ink on Application No

PCT/US 95/11814

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
1		

INTERNATIONAL SEARCH REPORTInt'l application No.
PCT/US95/11814**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 46-50 and 54-57 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically.
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/11814

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-214429	18-03-87	AU-B-	6032886	29-01-87
		JP-A-	62103058	13-05-87
		US-A-	4746737	24-05-88
-----	-----	-----	-----	-----
WO-A-9420527	15-09-94	AU-B-	6364794	26-09-94
		EP-A-	0688337	27-12-95
		FI-A-	954245	28-09-95
		NO-A-	953522	07-09-95
-----	-----	-----	-----	-----
WO-A-9532945	07-12-95	NONE		
-----	-----	-----	-----	-----